Next Article in Journal
The Impact of Urbanization on the Relationship between Carbon Storage Supply and Demand in Mega-Urban Agglomerations and Response Measures: A Case of Yangtze River Delta Region, China
Previous Article in Journal
The Evaluation of Rural Outdoor Dining Environment from Consumer Perspective
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Epidemiological Patterns of Cannabis- and Substance- Related Congenital Uronephrological Anomalies in Europe: Geospatiotemporal and Causal Inferential Study

by
Albert Stuart Reece
1,2,* and
Gary Kenneth Hulse
1,2
1
Division of Psychiatry, University of Western Australia, Crawley, WA 6009, Australia
2
School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2022, 19(21), 13769; https://doi.org/10.3390/ijerph192113769
Submission received: 19 September 2022 / Revised: 14 October 2022 / Accepted: 19 October 2022 / Published: 23 October 2022

Abstract

:
Introduction. Recent reports linking prenatal and community cannabis exposure to elevated uronephrological congenital anomaly (UCA) rates (UCAR’s) raise the question of its European epidemiology given recent increases in community cannabinoid penetration there. Methods. UCAR data from Eurocat. Drug use data from European Monitoring Centre for Drugs and Drug Addiction. Income from World bank. Results. UCAR increased across Spain, Netherlands, Poland and France. UCAR’s and cannabis resin THC increased simultaneously in France, Spain, Netherlands and Bulgaria. At bivariate analysis all UCA’s were related to cannabis herb and resin THC concentrations. All UCAR’s were bivariately related to cannabis metrics ordered by median minimum E-value (mEV) as hypospadias > multicystic renal disease > bilateral renal agenesis > UCA’s > hydronephrosis > posterior urethral valve > bladder exstrophy/epispadias. At inverse probability weighted multivariable analysis terms including cannabis were significant for the following series of anomalies: UCA’s, multicystic renal disease, bilateral renal agenesis, hydronephrosis, congenital posterior urethral valves from P = 1.91 × 10−5, 2.61 × 10−8, 4.60 × 10−15, 4.60 × 10−15 and 2.66 × 10−10. At geospatial analysis the same series of UCA’s were significantly related to cannabis from P = 7.84 × 10−15, 7.72 × 10−5, 0.0023, 6.95 × 10−5, and 8.82 × 10−5. 45/51 (88.2%) of E-value estimates and 31/51 (60.8%) of mEV’s >9. Conclusion. Analysis confirms a close relationship between cannabis metrics and all seven UCA’s and fulfill formal criteria for quantitative causal inference. Given the exponential cannabinoid genotoxicity dose–response relationship results provide a powerful stimulus to constrain community cannabinoid exposure including protection of the food chain to preserve the genome and epigenome of coming generations.

1. Introduction

1.1. Background

Recent reports demonstrate increasing concern at the genotoxic activities of cannabinoids expressed as congenital anomalies, cancer and aging [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23]. Recent epidemiological teratological reports have causally linked cannabis exposure with cardiovascular, chromosomal, central nervous system, limb, gastrointestinal, orofacial and body wall congenital anomalies [6,7,8,12,15,18,24,25,26,27,28,29,30,31]. A prominent part of cannabis teratology is uronephrological (urinary tract and renal) congenital anomalies (UCA’s) which have featured in reports of elevated rates of renal agenesis in Colorado [13], obstructive genitourinary defect in Hawaii [19], congenital posterior urethral valve, obstructive genitourinary defect, renal agenesis/hypoplasia, hypospadias and epispadias in USA [7] and hypospadias in Australia [8]. It was therefore of interest to investigate contemporary trends of this group of anomalies in Europe particularly given the rising triple convergence of prevalence of daily use, intensity of daily use and rising cannabinoid potency in widely available products in many countries across the European continent in the recent decade [20,32].

1.2. Cannabinoid Genotoxicity

Cannabinoid-related teratogenesis forms a subset of the large subject of cannabinoid genotoxicity which also includes cannabinoid related carcinogenesis [1,2,3,4,5,23] and cannabinoid induced acceleration of aging [7,11,12,23,33,34,35,36]. It is important to keep these broader issues in mind when considering the present investigation.

1.3. Genotoxic Mechanisms

Cannabinoid genotoxicity has long been known to occur by many mechanisms including gross abnormalities of sperm morphology [37,38], disruptions of normal oocyte division [39], many changes to oviduct and spermatogenic niche physiology [40,41,42], reduction in histone-protamine transfer during sperm DNA packing [42], chromosomal breaks [37,43,44,45], single- and double- stranded DNA breaks [43], mutagenic oxidation of DNA bases [43], chromosomal end-to-end fusions and translocations [37], likely breakage-fusion-bridge cycles in testicular oncogenesis [46,47], changes in DNA methylation patterns in sperm which are transmissible to following generations [48,49,50,51,52,53,54,55], reductions in histone synthesis [56,57,58,59,60] and reductions in post-translational modifications of histones [59,60,61] which are intergenerationally transmissible [62]. All of these mechanisms have been importantly implicated in cannabis related carcinogenesis [1,2,3,4,5,9,11,26,29,63]. Similarly these and other mechanisms have been implicated in the cannabis induced impairment of male fertility [64].

1.4. Exponential Dose-Response Effect Curve

It is important to appreciate that the genotoxic action of cannabinoids is strongly exponential with effects rising dramatically in the higher dose range. This has been noted both for the direct DNA mutagenicity [43,65,66,67,68,69,70,71,72] and for the mitochondrial metabolic reactions which underpin genomic and epigenomic reactions and provide substrates and energy to the genetic and epigenetic machinery [67,73,74,75,76,77,78]. This implies in turn that the rising triple confluence of prevalence–intensity-potency mentioned above can relatively abruptly place communities into a zone of high genotoxic risk result in a relatively sudden appearance of major genotoxic outcomes [20,32]. This likely accounts for adverse experiences such as recent French and German outbreaks of limblessness at up to sixty times the background rate in areas where many hectares are sown to cannabis [79,80,81,82]. Interestingly not only are babies being born without limbs but so too are the calves suggesting cannabinoid exposure via the food chain [79,80,81]. However, none of these effects are happening in nearby Switzerland where cannabinoids are not permitted in foodstuffs.

1.5. Lessons from VACTERL Syndrome

Interestingly a companion paper to this one has shown that the VACTERL syndrome (Vertebral, anorectal, cardiac, tracheo-esophageal fistulae/esophageal atresia, renal and limb anomalies) [83] was strongly and causally linked with European cannabinoid exposure [15,84]. Since renal anomalies are part of the VACTERL syndrome this finding also imputes renal abnormalities in the overall pattern of uronephrological congenital anomalies (UCA’s).

1.6. Study Questions

For these reasons it was considered important to assess UCA rates (UCAR’s) in response to increased cannabinoid exposure across many European countries, particularly as UCA’s appear to be a relatively sensitive mutagenic index of cannabinoid teratology. It was also considered important that this assessment be undertaken in a bivariate and multivariable context within a causal inferential framework, and in a spatiotemporal context which formally takes account of the native space-time environment in which this data was generated.

2. Methods

2.1. Data

The data on congenital anomaly rates was downloaded from the European Network of Population-Based Registries for the Epidemiological Surveillance of Congenital Anomalies (EUROCAT) website [85]. Annual data for all available anomalies was downloaded from both the summary and the detailed files for 14 nations for each individual year. The metric of interest was the total congenital anomaly rate which includes live births, stillbirths and cases where early termination for anomaly was practised. The total rate therefore represents the rate net of all the different birth exigencies to which pregnancies are subject. Nations were selected based upon most of their congenital anomaly data being available across most of the period 2010–2019. Data on national tobacco (percent daily tobacco use prevalence) and alcohol (litres of pure alcohol consumed per capita annually) consumption were obtained from the World Health Organization website [86]. The website of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) [87] was used to source data on drug use relating to cannabis, amphetamines and cocaine. The major metric of cannabis exposure was last month cannabis use data. This was supplemented by data on the tetrahydrocannabinol (THC) content of cannabis herb and resin provided in recent published reports [32] and by data on daily cannabis use which was also available from EMCDDA and was collated in recent Public Health reports [32]. Data on median household income data (in $USD) was derived from the World Bank sources [88].

2.2. National Assignment

Nations were grouped into either low and/or falling daily cannabis use or high and/or rising daily cannabis use based on a recent European epidemiological study (see Supplementary Figure S4 of reference [32]). In this way France, Germany, Italy, Belgium, Croatia, Norway, Portugal, Netherlands and Spain were categorized as nations experiencing increasing daily use. Finland, Hungary, Poland, Bulgaria and Sweden were nations which were experiencing low or falling levels of daily cannabis use.

2.3. Derived Data

Because several metrics of cannabis exposure were available it was possible to combine and group these in various ways. Thus last month cannabis use prevalence data was multiplied by the THC content of cannabis resin and herb to derive compound metrics from their product. These metrics were again multiplied by imputed daily cannabis use prevalence rates to derive more complex compound metrics for both cannabis resin and herb.

2.4. Data Imputation

Linear interpolation across years was used to complete missing data. This was especially so for daily cannabis use. For these 14 nations 59 data points on daily cannabis use were available from EMCDDA across this period. Linear interpolation was able to expand this dataset out to 129 datapoints (further details are provided within Results Section). There was no available data on cannabis resin THC concentration for Sweden. It was noted however that the resin: herb THC concentration was virtually in nearby Norway at 17.7. This ratio was therefore applied to the Swedish cannabis herb THC concentration data to derive estimates of the Swedish cannabis resin THC concentration. In a similar manner data for the cannabis resin THC concentration in Poland were not available from EMCDDA. The resin to herb THC concentration ratio of nearby Germany across time was used to estimate the resin THC content in Poland from the known Polish herb THC concentrations. Since geospatial analytical techniques do not tolerate missing data the dataset was completed by interpolation by the last observation carried forward or backwards for Croatia in 2018 and 2019 and Netherlands in 2010. Multiple imputation methods could not be used for these analyses as multiple imputation techniques have not been applied to panel or spatial multivariable regression methods.

2.5. Statistics

R Studio version 1.4.1717 based on R version 4.1.1 from the Comprehensive R Archive Network and the R Foundation for Statistical Computing was used for data processing [89]. The analysis was performed in December 2021. Data manipulation was performed using dplyr from the R Core team tidyverse [90]. Data were log transformed where appropriate as guided by the Shapiro–Wilks test to improve compliance with normality assumptions. ggplot2 from tidyverse was used for constructing graphs. Both ggplot2 and sf (simple features) [91] were used for drawing maps using both custom colour palettes and palettes provided in the viridis and viridisLite packages [92]. Bivariate maps were drawn with package colorplaner by William Murphy [93]. Illustrations are all original and have not been previously published. Linear regression was conducted in R Base. R package nlme was used for mixed effects regression [94]. Model reduction was by the classical technique of serial deletion of the least significant term to yield a final reduced model which is the model presented in all multivariable models. Combined techniques from R packages purrr and broom were used to process multiple linear models in a single pass virtually simultaneously [90,95,96]. The overall effect of covariates particularly of interactive multivariable models may be quantified and is denoted as the marginal effect. The R package margins was used to calculate the overall marginal effect [97].

2.6. Covariate Selection

With numerous different metrics of cannabis exposure available it was unclear which was the most appropriate set of covariates to select for each individual model. Use of excessive cannabis related covariates could lead to issues of collinearity, consumption of excessive degrees of freedom and a concomitant limitation of interactions which could be considered, or model mis-specification or imbalancing more generally.
The presence of multiple different metrics for cannabis consumption and exposure created a problem for analysis as it was not clear which was the most appropriate metric to employ for any particular model. Indiscriminate use of excessive covariates in a multivariable model would unnecessarily consume degrees of freedom and thereby restrict ability to assess interactions. Random forest regression using the R package ranger [98] with variable importance being formally assessed via the R package vip (variable importance plot) [99] was used to formally address this issue of variable selection. The most predictive of the covariates identified by this process were then entered into the regression modelling equations. Applicable tables from these analysis are presented below in the Results Section.

2.7. Panel and Geospatial Analysis

The R package plm [100] was utilized to conduct panel analysis across both space and time simultaneously using the “twoways” effect. The spatial weights matrix for temporospatial modelling was calculated using the edge and corner “queen” relationships using R package spdep (spatial dependency) [101]. The spatial panel random effects maximum likelihood (spreml) function from the package spml which allows detailed modelling and correction of model error structures [102,103] was used for geospatial modelling. Such models can produce up to four descriptive model coefficients which are can be used to verify the most appropriate error structure for the model. These coefficients are psi the serial correlation effect, rho the spatial coefficient, phi the random error effect and theta the spatial autocorrelation coefficient. The most appropriate error structure was chosen for each series of spatial models taking care to preserve the model error specification across related models. The appropriate error structure was determined by the backwards method from the full general model to the most specific model by the method which has previously been published [104]. Temporal lagging by one or two years was employed as indicated in both panel and geospatial models.

2.8. Causal Inference

This analysis deployed the formal tools of causal inference. Inverse probability weighting (ipw) is the analytical technique of choice to convert a purely observational study into a pseudo-randomised study from which it is entirely appropriate to draw causal inferences [105]. Inverse probability weighting was employed in all multivariable panel models presented. Inverse probability weights were calculated via the R package ipw. Similarly E-values (expected values) quantify the correlation required of some hypothetical unmeasured confounder covariate with both the exposure of concern and the outcome of interest in order to explain away some relationship which appears to be apparently causal in nature [106,107,108]. It therefore provides a quantitative measure of the robustness of the model to extraneous covariates which have not been accounted for within the measured parameters and is a popular and increasingly published form of sensitivity analysis. E-Values have a measure o uncertainty associated with them which can be quantified as a confidence interval and the 95% lower bound of this confidence interval is particularly relevant to situations of increased risk. For these reasons it has been extensively reported herein. E-Value estimates greater than 1.25 to indicate causality [109] and E-values larger than nine are described as being high [110]. The R package EValue was used for the calculation of both E-value estimates and their 95% lower bounds [111]. Both inverse probability weighting and E-values are foundational and pivotal techniques used in formal quantitative causal inferential methods in order to allow causal relationships to be assessed from real world observational studies and to control for the effect of observed and unobserved covariates respectively.

2.9. Data Availability

Raw datasets including 3800 lines of computation code in R has been made freely available through the Mendeley data repository at the following URL’s: https://data.mendeley.com/datasets/c6psrbr34j/1 and https://data.mendeley.com/datasets/vd6mt5r5jm/1.

2.10. Ethics

The Human Research Ethics Committee of the University of Western Australia provided ethical approval for the study to be undertaken 24 September 2021 (No. RA/4/20/4724). All methods were carried out in accordance with relevant guidelines and regulations and were concordant with the Declaration of Helsinki.

3. Results

3.1. Input Data

Supplementary Table S1 sets out the general overview of the covariates used in this study. As indicated 839 data points were downloaded from the EUROCAT database from the 14 nations shown and applying to the seven CA’s of urinary disorders, bilateral renal agenesis, bladder exstrophy or epispadias, congenital hydronephrosis, multicystic renal dysplasia and posterior urethral valve or prune belly. Covariates for drug exposure including various primary and compound metrics of cannabis exposure are as indicted in the table along with median household income data.
Data on daily drug use by European nation and year was examined and was found to be incomplete as indicated in Supplementary Table S2 with 59 points available. In order to allow this information to be used in comparative studies a further 70 datapoints were added to this data by linear interpolation. This augmented dataset is shown in Supplementary Table S3.

3.2. Bivariate Analysis

Figure 1 shows the relationship between the rates of the various UCA’s and the substance tobacco, alcohol, daily cannabis use interpolated, amphetamine and cocaine exposure. It appears that tobacco exposure is not associated with any UCA incidence. There does seem to be a positive relationship between annual alcohol consumption and multicystic renal disease and posterior urethral valve as those regression lines have a positive slope. Amphetamine and cocaine exposure appear to be positively related to all defects mentioned. Daily cannabis interpolated appears to be related to hydronephrosis, multicystic renal disease and urinary anomalies globally.
Figure 2 illustrates the relationship between various cannabis exposure metrics and rates of the various UCA’s. Many of the regression lines appear to be positively up-sloping including those for last month cannabis use, the THC concentration of cannabis herb and resin, and most of the compound cannabis metrics.
Figure 3 shows the rates of UCA’s across Europe for the past decade. Rates seem to have risen in Spain, Portugal, France, Belgium, Bulgaria, Sweden and Croatia but have declined in Germany.
Rates of bilateral renal agenesis are shown in Figure 4. The appear to have increased in Spain, Norway, Germany, Netherlands, Belgium and Croatia but reduced in Poland.
Rates of posterior urethral valve are shown in Figure 5. Rates increased in Spain, Portugal, Poland, France, Bulgaria and Sweden but reduced in Germany. Rates in the low countries and France fluctuated.
Rates of multicystic renal disease are shown in Figure 6. Rates increased in France, Bulgaria, Norway, Poland, Netherlands, Belgium, Croatia and Sweden and fluctuated in Germany.
Figure 7 shows the rate of the compound metric last month cannabis use: cannabis resin THC concentration. It has increased across the continent but the rises in Spain, Portugal, Netherland and France were most accentuated.
Figure 2. Bivariate plots of selected uronephrological congenital anomalies against various metrics of cannabis exposure.
Figure 2. Bivariate plots of selected uronephrological congenital anomalies against various metrics of cannabis exposure.
Ijerph 19 13769 g002
Figure 3. Time sequential map-graph of log (uronephrological anomaly rate) across surveyed European nations over time.
Figure 3. Time sequential map-graph of log (uronephrological anomaly rate) across surveyed European nations over time.
Ijerph 19 13769 g003
Figure 4. Time sequential map-graph of log (bilateral renal agenesis anomaly rate) across surveyed European nations over time.
Figure 4. Time sequential map-graph of log (bilateral renal agenesis anomaly rate) across surveyed European nations over time.
Ijerph 19 13769 g004
Figure 5. Time sequential map-graph of log (congenital posterior urethral valve rate) across surveyed European nations over time.
Figure 5. Time sequential map-graph of log (congenital posterior urethral valve rate) across surveyed European nations over time.
Ijerph 19 13769 g005
Figure 6. Time sequential map-graph of log (Multicystic renal disease rate) across surveyed European nations over time.
Figure 6. Time sequential map-graph of log (Multicystic renal disease rate) across surveyed European nations over time.
Ijerph 19 13769 g006
Figure 7. Time sequential map-graph of last month cannabis use: cannabis resin THC concentration across surveyed European nations over time.
Figure 7. Time sequential map-graph of last month cannabis use: cannabis resin THC concentration across surveyed European nations over time.
Ijerph 19 13769 g007

3.2.1. Bivariate Graphs

Figure 8 is a bivariate plot of the co-distribution of uronephrolgical congenital disorders and last month cannabis use: cannabis resin THC concentration across Europe over the decade. One reads the plot by noting the areas which turn purple or crimson which signify a high distribution of both covariates. The significance of the other colours is indicated in the colorplane key. The series of graphs makes clear the co-emergence of high rates of both uronephrolgical disease and the compound cannabis use metric in France, Netherlands and Bulgaria across the decade.
Figure 9 is a similar bivariate series of maps showing the co-emergence of high rates of bilateral renal agenesis and the compound cannabis exposure metric in Netherlands.
Figure 10 plays the same role for rates of posterior urethral valve. The co-emergence of high rates in France and Netherlands is made plain by this graphic.
Figure 11 performs a similar function for multicystic renal disease. The co-emergence of high rates in France, Netherlands and Bulgaria is shown.
Figure 8. Colorplane bivariate time sequential map-graph of log (uronephrological congenital anomaly rate) by last month cannabis use: cannabis resin THC concentration across surveyed European nations over time.
Figure 8. Colorplane bivariate time sequential map-graph of log (uronephrological congenital anomaly rate) by last month cannabis use: cannabis resin THC concentration across surveyed European nations over time.
Ijerph 19 13769 g008
Figure 9. Colorplane bivariate time sequential map-graph of log (bilateral renal agenesis congenital anomaly rate) by last month cannabis use: cannabis resin THC concentration across surveyed European nations over time.
Figure 9. Colorplane bivariate time sequential map-graph of log (bilateral renal agenesis congenital anomaly rate) by last month cannabis use: cannabis resin THC concentration across surveyed European nations over time.
Ijerph 19 13769 g009
Figure 10. Colorplane bivariate time sequential map-graph of log (posterior urethral valve congenital anomaly rate) by last month cannabis use: cannabis resin THC concentration across surveyed European nations over time.
Figure 10. Colorplane bivariate time sequential map-graph of log (posterior urethral valve congenital anomaly rate) by last month cannabis use: cannabis resin THC concentration across surveyed European nations over time.
Ijerph 19 13769 g010
Figure 11. Colorplane bivariate time sequential map-graph of log (multicystic renal disease congenital anomaly rate) by last month cannabis use: cannabis resin THC concentration across surveyed European nations over time.
Figure 11. Colorplane bivariate time sequential map-graph of log (multicystic renal disease congenital anomaly rate) by last month cannabis use: cannabis resin THC concentration across surveyed European nations over time.
Ijerph 19 13769 g011

3.2.2. Bivariate Overview

Nations were grouped into those where daily cannabis use was increasing or high and those where it is not based on recent epidemiological reports [32]. When all CA’s are groups together the appearances seen in Figure 12 are shown. Nations where daily use is increasing are shown to have higher rates of UCA’s at linear regression (β-est. = 0.3121, t = 2.687, p = 0.0073; model Adj.R.Squ. = 0.074, F = 75.22, df = 12, 837, p = 0074). The E-value estimate for this effect is 1.71 with a 95% lower bound on the confidence interval (mEV) of 1.29 which exceeds the quoted threshold fror causality of 1.25 [109]
When this comparison is done in an anomaly-specific manner the appearances shown in Figure 13 are seen. When these differences are studied formally by mixed effects regression the rate in the countries with increasing daily use is significantly higher than the remainder (β-est. = 0.2048, t = 3.943, p = 8.73 × 10−5; model AIC = 1755.781, Log.Lik = −872.891). This effect is associated with an E-value estimate of 1.97 and mEV = 1.57.

3.2.3. Bivariate Linear Regressions

The regression lines shown graphically in Figure 1 and Figure 2 may be studied by multiple bivariate linear regression models simultaneously using the purrr-broom workflow in R. when this is performed 85 regression models are derived which are listed in Supplementary Table S2 in descending order of mEV. Interestingly daily cannabis use appears at the top of this list of models.
From this list those which have positive regression coefficients and significant p-values may be extracted. 37 such models are retained in this way which are listed in Table 1.

3.3. Covariate Selection

Having identified so many bivariate relationships of interest the next question relates to how these different covariates might perform in a multivariable context. However, given that there are 13 substance exposure covariates it is not entirely obvious which might be the best combination of covariates to use in anomaly-specific regression equations.
This issue was addressed formally by the use of random Forest regression in tandem with variable importance assessment using the R packages ranger and vip. When this was done for the overall UCA’s and for multicystic renal disease, bilateral renal agenesis, hydronephrosis and posterior urethral valve the variable importance tables shown in Supplementary Tables S3–S7 were derived.

3.4. Multivariable Regressions

3.4.1. IPW Panel Regression

These covariates were then used to define multivariable inverse probability weighted panel regression models for a series of multivariable models relating to the five congenital uronephrological disorders of interest. The inverse probability weighting is of considerable importance and allows the analysis to move from that of an observational study only to a pseudo-randomized milieu from which is it appropriate to draw causal inferences.
Supplementary Table S8 describes three such final inverse probability weighted panel regression models for uronephrological disease as a whole. Additive, interactive and temporally lagged models are shown. In each one cannabis metrics are significant in final models and survive model reduction, have positive regression coefficients and are highly statistically significant.
This pattern is continued across the other anomalies, namely multicystic renal dysplasia, bilateral renal agenesis, hydronephrosis and posterior urethral valve syndrome as shown in Supplementary Tables S9–S12.
This result is important because it means directly that in this set of congenital anomalies the strong trends identified at bivariate regression persist after multivariable adjustment in an inverse probability weighted and therefore casual paradigm.

3.4.2. Geospatial Regression

The next issue to consider was whether these relationships would continue when considered formally in their native space-time context in which major methodological concerns such as random errors, serial correlation, spatial correlation and spatial autocorrelation would be properly accounted for and managed.
Supplementary Figure S1 presents maps of the initial, edited and final geospatial links between countries which were derived and used as the basis for the sparse spatial weights matrix used in the spatial regressions.
Table 2 presents additive, interactive and lagged geospatial models for uronephrological disorders broadly. The pattern identified earlier in panel regression is continued with some cannabis-related terms in each model persisting in the final model after model reduction and maintaining high levels of statistical significance from 7.84 × 10−15 in the case of the first additive model.
This pattern is continued when multicystic renal disease is considered as shown in Table 3. In each model the effect of cannabis-related covariates is overwhelmingly in the positive direction.
Similar results are also seen when bilateral renal agenesis is considered in interactive and lagged models as shown in Table 4.
When hydronephrosis is considered the pattern is continued in additive, interactive and models lagged to one year, but the signal fades by two years of temporal lagging (Table 5).
The pattern is continued and confirmed when posterior urethral valve syndromes are considered as shown in Table 6. In each case terms including cannabis metrics persist after adjustment in final models, have positive regression coefficients and are statistically significant.

3.5. Causal Inference

E-Values

E-values may be extracted from each of these regression models. Table 7 does this for panel models and Table 8 does this for spatial models.
Both lists are combined in Table 9 where 51 such E-value pairs are listed in descending order of mEV. The prominence of daily cannabis use interpolated at the head of the table is noted as is the high level of statistical significance of the E-values returned.
Figure 12. Overall rate of log (uronephrolgical congenital anomaly rate) against time by rising of falling daily cannabis use rates (see Methods section for country classification).
Figure 12. Overall rate of log (uronephrolgical congenital anomaly rate) against time by rising of falling daily cannabis use rates (see Methods section for country classification).
Ijerph 19 13769 g012
Figure 13. Rate of log (uronephrological congenital anomaly rate) against time by rising of falling daily cannabis use rates by congenital anomaly.
Figure 13. Rate of log (uronephrological congenital anomaly rate) against time by rising of falling daily cannabis use rates by congenital anomaly.
Ijerph 19 13769 g013
Table 1. Positive Significant Slopes from Bivariate Linear Regressions.
Table 1. Positive Significant Slopes from Bivariate Linear Regressions.
AnomalySubstanceMean Anomaly RateEstimateStd.ErrorSigmat_statisticp-ValueE-Value EstimateE-Value Lower Bound
Multicystic Renal DysDaily.Interpol.3.465530.44479.59530.90073.17290.00194.57 × 10132.66 × 105
HydronephrosisDaily.Interpol.13.845527.87718.78970.82503.17160.00204.52 × 10132.62 × 105
UrinaryDaily.Interpol.35.447514.36845.35830.50292.68150.00843.90 × 10112.27 × 103
Multicystic Renal DysLMCannabis_Herb3.465511.45223.02670.86883.78372.43 × 10−43.24 × 105656.0696
HypospadiasHerb19.20374.91961.37270.45463.58385.15 × 10−43.78 × 104174.7051
Multicystic Renal DysLM_Cannabis3.465511.44773.65140.88373.13520.00222.63 × 105167.9388
UrinaryLMCannabis_Herb35.44755.08711.72320.49472.95210.00382.32 × 10446.5273
HydronephrosisDaily.Interpol.13.84556.58202.10940.82023.12040.00232.97 × 10330.0042
UrinaryHerb35.44753.81641.27060.49413.00360.00322.26 × 10322.7009
HydronephrosisLMCannabis_Herb13.84557.31282.89500.83102.52600.01286.01 × 10311.6605
Multicystic Renal DysLMCannabis_Resin3.46553.05580.73660.88204.14886.81 × 10−546.305010.0602
Multicystic Renal DysHerb3.46555.58612.30830.89762.42000.0170575.82975.3720
Bilat Renal AgenesisHerb1.36173.93631.64240.63862.39670.0181545.30915.0547
Multicystic Renal DysLM.Cannabis_x_Herb.THC_x_Daily.Interpol.3.46552.81871.06850.91222.63790.009532.77203.5552
Posterior Ureth ValvHerb1.30623.84001.70520.66302.25190.0261388.43273.4114
Multicystic Renal DysLM.Cannabis_x_Resin.THC_x_Daily.Interpol.3.46551.64370.49550.92723.31710.00139.50883.2871
HydronephrosisLM.Cannabis_x_Herb.THC_x_Daily.Interpol.13.84552.41670.98250.83882.45970.015427.01222.8132
UrinaryLMCannabis_Resin35.44751.07330.41080.49192.61290.010314.04982.6800
HydronephrosisCocaine13.84550.49160.09620.77295.10791.24 × 10−62.96632.2125
UrinaryLM.Cannabis_x_Herb.THC_x_Daily.Interpol.35.44751.33840.59440.50742.25170.026321.53612.0829
UrinaryCocaine35.44750.26570.05900.47384.50411.56 × 10−52.71912.0031
UrinaryLM.Cannabis_x_Resin.THC_x_Daily.Interpol.35.44750.67380.26640.49852.52910.01306.29871.9731
Multicystic Renal DysCocaine3.46550.46600.10630.85334.38572.50 × 10−52.67231.9630
HydronephrosisLM.Cannabis_x_Resin.THC_x_Daily.Interpol.13.84551.16560.46270.86592.51890.01346.26451.9582
HypospadiasCocaine19.20370.22300.06080.45343.66793.86 × 10−42.50431.7674
Posterior Ureth ValvLMCannabis_Resin1.30621.27290.57450.68802.21540.028910.24491.7331
HydronephrosisLMCannabis_Resin13.84551.54450.72150.86392.14070.03469.64881.5671
Bladder Extr/EpispadLMCannabis_Resin0.66570.81710.38480.46082.12350.03619.51571.5282
HydronephrosisResin13.84551.98760.96240.86522.06520.041415.66311.4781
UrinaryAmphetamine35.44750.17650.06220.49592.83770.00532.10951.4480
Bladder Extr/EpispadCocaine0.66570.15110.05480.44052.75450.00682.07381.4166
HydronephrosisAmphetamine13.84550.27890.10390.82832.68560.00832.05661.3940
HypospadiasAmphetamine19.20370.15770.06030.46672.61420.01032.05981.3754
Multicystic Renal DysResin3.46552.10841.03830.93342.03060.044815.10601.3692
Bilat Renal AgenesisCocaine1.36170.20170.07930.63682.54430.01222.00181.3404
Posterior Ureth ValvAnnual_Alcohol1.30620.09580.03250.65372.94500.00391.54621.2646
Multicystic Renal DysAmphetamine3.46550.25370.11290.90052.24640.02651.90671.2203
Table 2. Geotemporospatial Regressions for Uronephrological Congenital Anomalies as a Group.
Table 2. Geotemporospatial Regressions for Uronephrological Congenital Anomalies as a Group.
Parameter ValuesModel Parameters
ParameterEstimate (C.I.)p-ValueParameterValueSignificance
Additive
Rate ~ Tobacco + Alcohol + LM.Cannabis_x_Herb.THC_x_Daily.Interpol. + LM.Cannabis_x_Resin.THC_x_Daily.Interpol. + LM.Cannabis_x_Herb.THC + Daily.Interpol. + Amphetamines + Cocaine + Income
Tobacco0.06 (0.04, 0.07)8.09 × 10−12rho−0.56772.99 × 10−6
Alcohol0.03 (0, 0.06)0.0394lambda0.42061.45 × 10−5
LM.Cannabis_x_Herb.THC_x_Daily.Interpol.−4.7 (−5.97, −3.43)4.05 × 10−13
LM.Cannabis_x_Herb.THC14.1 (10.53, 17.67)7.84 × 10−15
Cocaine0.23 (0.12, 0.33)2.82 × 10−5
Income0 (0, 0)1.23 × 10−14
Interactive
Rate ~ Tobacco * LM.Cannabis_x_Herb.THC_x_Daily.Interpol. * LM.Cannabis_x_Resin.THC_x_Daily.Interpol. + LM.Cannabis_x_Resin.THC + Alcohol + Daily.Interpol. + Amphetamines + Cocaine + Income
Tobacco−0.04 (−0.07, −0.01)0.0067phi6.15540.0464
LM.Cannabis_x_Resin.THC_x_Daily.Interpol.−11.75 (−15.66, −7.83)4.18 × 10−9rho−0.56438.32 × 10−7
Daily.Interpol.19.94 (2.57, 37.3)0.024429lambda0.57316.79 × 10−10
Tobacco: LM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.51 (0.34, 0.67)3.07 × 10−9
LM.Cannabis_x_Herb.THC_x_Daily.Interpol.: LM.Cannabis_x_Resin.THC_x_Daily.Interpol.53.87 (26.64, 81.11)0.0001
Tobacco: LM.Cannabis_x_Herb.THC_x_Daily.Interpol.: LM.Cannabis_x_Resin.THC_x_Daily.Interpol.−2.33 (−3.51, −1.14)0.0001
1 Lag
Rate ~ Tobacco * LM.Cannabis_x_Herb.THC_x_Daily.Interpol. + Daily.Interpol. + LM.Cannabis_x_Resin.THC_x_Daily.Interpol. + Alcohol + Daily.Interpol. + Amphetamines + Cocaine + Income
Tobacco0.04 (0.02, 0.07)0.0003rho0.20130.497
Daily.Interpol.−31.9 (−53.26, −10.54)0.0033lambda0.06960.782
LM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.85 (0.18, 1.53)0.0130
Alcohol0.07 (0.02, 0.12)0.0106
Cocaine0.52 (0.28, 0.75)1.52 × 10−5
Income0 (0, 0)0.0001
Legend: lm—linear modelling; Left Hand Side—Dependent Variable; Right Hand side—List of independent covariates; ~—Separator between left and right hand sides of a model formula; +—Additive relationship between covariates; *—Interactive relationship between covariates—includes additive relationships; AUD—Alcohol Use Disorder; phi—Random error coefficient; psi—Serial correlation coefficient.; rho—Spatial error coefficient; lambda—Spatial error autocorrelation coefficient.
Table 3. Geotemporospatial Regressions for Multicystic Renal Disease Congenital Anomalies.
Table 3. Geotemporospatial Regressions for Multicystic Renal Disease Congenital Anomalies.
Parameter ValuesModel Parameters
ParameterEstimate (C.I.)p-ValueParameterValueSignificance
Additive
Rate ~ Tobacco + Alcohol + LM.Cannabis_x_Herb.THC_x_Daily.Interpol. + LM.Cannabis_x_Resin.THC_x_Daily.Interpol. + LM.Cannabis_x_Resin.THC + Daily.Interpol. + Amphetamines + Cocaine + Income
Tobacco0.12 (0.06, 0.18)9.17 × 10−5psi0.54954.92 × 10−10
LM.Cannabis_x_Resin.THC1.17 (0.11, 2.23)0.0310rho−0.57770.000168
Income0 (0, 0)0.0001lambda0.50100.000692
Interactive
Rate ~ Tobacco * LM.Cannabis_x_Resin.THC_x_Daily.Interpol. + Daily.Interpol. + LM.Cannabis_x_Herb.THC_x_Daily.Interpol. + LM.Cannabis_x_Resin.THC + Alcohol + Amphetamines + Cocaine + Income
Tobacco0.12 (0.06, 0.18)9.17 × 10−5psi0.54954.92 × 10−10
LM.Cannabis_x_Resin.THC1.17 (0.11, 2.23)0.0310rho−0.57770.000168
Income0 (0, 0)0.0001lambda0.50100.000692
2 Lags
Rate ~ Tobacco * LM.Cannabis_x_Resin.THC + Daily.Interpol. + LM.Cannabis_x_Resin.THC_x_Daily.Interpol. + LM.Cannabis_x_Herb.THC_x_Daily.Interpol. + Alcohol + + Amphetamines + Cocaine + Income
Tobacco0.06 (0.02, 0.1)0.0060psi0.58341.62 × 10−9
LM.Cannabis_x_Resin.THC3.9 (1.97, 5.84)7.72 × 10−5rho0.70443.78 × 10−16
Daily.Interpol.74.8 (28.64, 120.96)0.0015lambda−0.60937.22 × 10−08
LM.Cannabis_x_Herb.THC_x_Daily.Interpol.−7.05 (−12.74, −1.36)0.0152
Amphetamines−0.27 (−0.53, 0)0.0493
Legend—See Table 2.
Table 4. Geotemporospatial Regressions for Bilateral Renal Agenesis Congenital Anomalies.
Table 4. Geotemporospatial Regressions for Bilateral Renal Agenesis Congenital Anomalies.
Parameter ValuesModel Parameters
ParameterEstimate (C.I.)p-ValueParameterValueSignificance
Additive
Rate ~ Tobacco + Alcohol + LM.Cannabis_x_Herb.THC_x_Daily.Interpol. + LM.Cannabis_x_Resin.THC_x_Daily.Interpol. + LM.Cannabis_x_Resin.THC + Resin + Daily.Interpol. + Herb + Amphetamines + Cocaine + Income
Alcohol0.13 (0.07, 0.18)3.62 × 10−6rho0.62386.72 × 10−10
Income0 (0, 0)1.10 × 10−8lambda−0.54901.92 × 10−6
Interactive
Rate ~ Tobacco * LM.Cannabis_x_Resin.THC_x_Daily.Interpol. + Daily.Interpol. + LM.Cannabis_x_Herb.THC_x_Daily.Interpol. + LM.Cannabis_x_Resin.THC + Alcohol + Herb + Amphetamines + Cocaine + Income
LM.Cannabis_x_Resin.THC_x_Daily.Interpol.4.06 (0.57, 7.55)0.0228rho0.63142.39 × 10−11
Alcohol0.14 (0.09, 0.2)4.66 × 10−7lambda−0.53461.34 × 10−6
Income0 (0, 0)1.49 × 10−8
LM.Cannabis_x_Herb.THC: LM.Cannabis_x_Resin.THC_x_Daily.Interpol.−0.15 (−0.3, −0.01)0.0327
2 Lags
Rate ~ Tobacco * Daily.Interpol. + LM.Cannabis_x_Resin.THC_x_Daily.Interpol. + LM.Cannabis_x_Herb.THC_x_Daily.Interpol. + LM.Cannabis_x_Resin.THC + Alcohol + Amphetamines + Cocaine + Income
LM.Cannabis_x_Resin.THC2.33 (0.83, 3.83)0.0023rho0.55796.16 × 10−5
Alcohol0.18 (0.11, 0.24)6.12 × 10−8lambda−0.44730.00217
Cocaine0.58 (0.26, 0.9)0.0004
Resin0 (0, 0)0.0033
Tobacco: Daily.Interpol.−1.87 (−2.9, −0.84)0.0004
Legend—See Table 2.
Table 5. Geotemporospatial Regressions for Hydronephrosis Congenital Anomalies.
Table 5. Geotemporospatial Regressions for Hydronephrosis Congenital Anomalies.
Parameter ValuesModel Parameters
ParameterEstimate (C.I.)p-ValueParameterValueSignificance
Additive
Rate ~ Tobacco + Alcohol + Daily.Interpol. + LM.Cannabis_x_Herb.THC_x_Daily.Interpol. + LM.Cannabis_x_Resin.THC_x_Daily.Interpol. + Herb + Amphetamines + Cocaine + Income
Tobacco−0.04 (−0.07, 0)0.0283psi0.45943.24 × 10−7
Daily.Interpol.67.26 (23.46, 111.06)0.0026rho0.45130.00694
LM.Cannabis_x_Herb.THC_x_Daily.Interpol.−9.26 (−16.96, −1.56)0.0185lambda−0.50730.00149
Herb12.02 (6.1, 17.94)6.95 × 10−5
Interactive
Rate ~ Tobacco * Daily.Interpol. + Resin + Herb + LM.Cannabis_x_Herb.THC_x_Daily.Interpol. + LM.Cannabis_x_Resin.THC_x_Daily.Interpol. + Alcohol + Amphetamines + Cocaine + Income
Tobacco−0.05 (−0.09, −0.01)0.0064psi0.50951.42 × 10−9
Herb9.93 (4.34, 15.53)0.0005rho0.43240.0151
LM.Cannabis_x_Herb.THC_x_Daily.Interpol.−5.24 (−9.59, −0.89)0.0182lambda−0.48300.00603
Tobacco: Daily.Interpol.2.9 (1.29, 4.51)0.0004
1 Lag
Rate ~ Tobacco + Herb * Resin + LM.Cannabis_x_Resin.THC_x_Daily.Interpol. * Daily.Interpol. + Herb + LM.Cannabis_x_Herb.THC_x_Daily.Interpol. + Alcohol + Amphetamines + Cocaine + Income
Herb6.01 (2.26, 9.76)0.0017psi0.51171.30E−9
Cocaine0.35 (0.1, 0.59)0.0058rho−0.53420.00382
lambda0.40130.0324
2 Lags
Rate ~ Tobacco * Herb + LM.Cannabis_x_Resin.THC_x_Daily.Interpol. + Daily.Interpol. + Resin + Alcohol + Amphetamines + Cocaine + Income
Resin−2.46 (−4.02, −0.9)0.0020psi0.8338< 2.22 × 10−16
Tobacco: Herb−0.25 (−0.42, −0.08)0.0033rho0.66506.20 × 10−13
lambda−0.59455.88 × 10−7
Legend—See Table 2.
Table 6. Geotemporospatial Regressions for Congenital Posterior Urethral Valve Congenital Anomalies.
Table 6. Geotemporospatial Regressions for Congenital Posterior Urethral Valve Congenital Anomalies.
Parameter ValuesModel Parameters
ParameterEstimate (C.I.)p-ValueParameterValueSignificance
Additive
Rate ~ Tobacco + Alcohol + LM.Cannabis_x_Herb.THC_x_Daily.Interpol. + LM.Cannabis_x_Resin.THC_x_Daily.Interpol. + LM.Cannabis_x_Resin.THC + Daily.Interpol. + Resin + Herb + Amphetamines + Cocaine + Income
Tobacco0.04 (0.02, 0.06)0.0001psi0.23110.0177
Alcohol0.15 (0.08, 0.22)9.98 × 10−6rho−0.51956.58 × 10−5
LM.Cannabis_x_Herb.THC_x_Daily.Interpol.−10.18 (−14.3, −6.06)1.29 × 10−6lambda0.52522.31 × 10−5
LM.Cannabis_x_Resin.THC_x_Daily.Interpol.3.09 (1.55, 4.64)8.82 × 10−5
Herb4.77 (1.87, 7.67)0.0013
Amphetamines−0.19 (−0.36, −0.03)0.0218
Cocaine0.51 (0.3, 0.71)1.54 × 10−6
Interactive
Rate ~ Tobacco * Daily.Interpol. + LM.Cannabis_x_Herb.THC_x_Daily.Interpol. + LM.Cannabis_x_Resin.THC_x_Daily.Interpol. + Herb + Alcohol + Amphetamines + Cocaine + Income
Tobacco0.04 (0.02, 0.06)0.0001psi0.23110.0177
LM.Cannabis_x_Herb.THC_x_Daily.Interpol.−10.18 (−14.3, −6.06)1.29 × 10−6rho−0.51956.58 × 10−5
LM.Cannabis_x_Resin.THC_x_Daily.Interpol.3.09 (1.55, 4.64)8.82 × 10−5lambda0.52522.33 × 10−5
Herb4.77 (1.87, 7.67)0.0013
Alcohol0.15 (0.08, 0.22)9.98 × 10−6
Amphetamines−0.19 (−0.36, −0.03)0.0218
Cocaine0.51 (0.3, 0.71)1.54 × 10−6
1 Lag
Rate ~ Tobacco * LM.Cannabis_x_Resin.THC_x_Daily.Interpol. + Daily.Interpol. + LM.Cannabis_x_Herb.THC_x_Daily.Interpol. + LM.Cannabis_x_Herb.THC + Alcohol + Daily.Interpol. + Amphetamines + Cocaine + Income
Tobacco0.07 (0.02, 0.11)0.0027psi0.34190.0013
LM.Cannabis_x_Resin.THC_x_Daily.Interpol.2.65 (0.59, 4.71)0.0114rho−0.47160.00201
Daily.Interpol.91.2 (37.3, 145.1)0.0009lambda0.50180.000476
LM.Cannabis_x_Herb.THC_x_Daily.Interpol.−18.6 (−28.09, −9.11)0.0001
LM.Cannabis_x_Herb.THC23.1 (11.16, 35.04)0.0002
Cocaine−0.57 (−0.97, −0.16)0.0057
Income0 (0, 0)0.0036
2 Lags
Rate ~ Tobacco * LM.Cannabis_x_Resin.THC_x_Daily.Interpol. + Daily.Interpol. + LM.Cannabis_x_Herb.THC_x_Daily.Interpol. + LM.Cannabis_x_Herb.THC + Alcohol + Daily.Interpol. + Amphetamines + Cocaine + Income
Tobacco0.06 (0.01, 0.1)0.0241psi0.32060.00367
LM.Cannabis_x_Resin.THC_x_Daily.Interpol.3.06 (0.45, 5.67)0.0217rho−0.37170.06365
LM.Cannabis_x_Herb.THC_x_Daily.Interpol.−7.99 (−13.97, −2.01)0.0087lambda0.41260.0323
Legend—See Table 2.
Table 7. E-Values from Multivariable Panel Regression Models.
Table 7. E-Values from Multivariable Panel Regression Models.
AnomalyTermp-ValueE-Value EstimateLower Bound E-Value
 
UrinaryAdditive
LM.Cannabis_x_Herb.THC_x_Daily.Interpol.0.00129.033.23
LM.Cannabis_x_Herb.THC1.91 × 10−56.69 × 1081.22 × 105
Interactive
LM.Cannabis_x_Herb.THC_x_Daily.Interpol.0.016515.852.38
LM.Cannabis_x_Resin.THC0.007967.004.73
2 Lags
Tobacco: Resin6.32 × 10−52.862.02
Multicystic Renal DiseaseAdditive
LM.Cannabis_x_Resin.THC2.61 × 10−821.289.43
Interactive
Daily.Interpol.0.04986.23 × 106313.74
Tobacco: Daily.Interpol.: LM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.00631.61 × 10556.63
2 Lags
Daily.Interpol.0.04331.18 × 101031.15 × 105
LM.Cannabis_x_Resin.THC0.0097606.018.35
LM.Cannabis_x_Herb.THC_x_Daily.Interpol.0.026959.952.51
Bilateral Renal AgenesisAdditive
Resin0.02736.581.62
Daily.Interpol.0.00031.21 × 10171.95 × 108
Interactive
Daily.Interpol.5.10 × 10−83.41 × 101223.30 × 1081
2 Lags
LM.Cannabis_x_Resin.THC4.60 × 10−1542.8122.36
HydronephrosisAdditive
Daily.Interpol.5.45 × 10−65.81 × 10281.24 × 1017
LM.Cannabis_x_Herb.THC_x_Daily.Interpol.0.00047.243.13
Herb0.00026.62 × 104303.56
Interactive
Daily.Interpol.0.00381.45 × 10911.36 × 1031
Resin0.00462.73 × 1029.28
Herb1.75 × 10−73.51 × 1092.01 × 106
LM.Cannabis_x_Herb.THC_x_Daily.Interpol.0.004011.73.06
2 Lags
Herb1.87 × 10−52.33 × 1072.03 × 104
Posterior Urethral ValveAdditive
LM.Cannabis_x_Resin.THC_x_Daily.Interpol.2.25 × 10−710.525.47
Interactive
LM.Cannabis_x_Resin.THC_x_Daily.Interpol.3.38 × 10−62.652.02
LM.Cannabis_x_Resin.THC2.66 × 10−1043.5617.85
2 Lags
Daily.Interpol.: LM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.04818.15 × 1041.89
Table 8. E-Values from Spatial Models.
Table 8. E-Values from Spatial Models.
AnomalyTermp-ValueE-Value EstimateLower Bound E-Value
UrinaryAdditive
LM.Cannabis_x_Herb.THC7.84 × 10−152.18 × 10131.14 × 1010
Interactive
Daily.Interpol.0.02445.96 × 1017285.07
Tobacco: LM.Cannabis_x_Resin.THC_x_Daily.Interpol.3.07 × 10−95.013.38
LM.Cannabis_x_Herb.THC_x_Daily.Interpol.: LM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.00013.34 × 10474.98 × 1023
1 Lag
LM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.01308.582.10
Multicystic Renal DiseaseAdditive
LM.Cannabis_x_Resin.THC0.03109.681.60
Interactive
LM.Cannabis_x_Resin.THC0.03109.681.60
2 Lags
LM.Cannabis_x_Resin.THC7.72 × 10−56.62 × 103119.49
Daily.Interpol.0.00156.01 × 10671.67 × 1026
Bilateral Renal AgenesisInteractive
LM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.02283.54 × 1035.18
2 Lags
LM.Cannabis_x_Resin.THC0.0023162.579.09
HydronephrosisAdditive
Daily.Interpol.0.002682.567.02
Herb6.95 × 10−54.51 × 1083.52 × 104
Interactive
Herb0.00056.89 × 1061.46 × 103
Tobacco: Daily.Interpol.0.0004161.3113.62
1 Lag
Herb0.00171.23 × 1051258.11
Posterior Urethral ValveAdditive
LM.Cannabis_x_Resin.THC_x_Daily.Interpol.8.82 × 10−5954.9543.51
Herb0.00132.74 × 10583.66
Interactive
LM.Cannabis_x_Resin.THC_x_Daily.Interpol.8.82 × 10−5955.3243.52
Herb0.00132.73 × 10483.68
1 Lag
LM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.0114252.915.45
Daily.Interpol.0.00095.23 × 10721.08 × 1030
LM.Cannabis_x_Herb.THC0.00024.09 × 10181.39 × 109
2 Lags
LM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.0217365.383.75
Table 9. All E-Values Ordered by Minimum E-Value.
Table 9. All E-Values Ordered by Minimum E-Value.
No.AnomalyRegressionModel TypeTermp-ValueE-Value EstimateLower Bound E-Value
1Bilateral Renal AgenesisPanelInteractiveDaily.Interpol.5.10 × 10−83.41 × 101223.30 × 1081
2HydronephrosisPanelInteractiveDaily.Interpol.0.00381.45 × 10911.36 × 1031
3Posterior Urethral ValveSpatial1 LagDaily.Interpol.0.00095.23 × 10721.08 × 1030
4Multicystic Renal DiseaseSpatial2 LagsDaily.Interpol.0.00156.01 × 10671.67 × 1026
5UrinarySpatialInteractiveLM.Cannabis_x_Herb.THC_x_Daily.Interpol.: LM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.00013.34 × 10474.98 × 1023
6HydronephrosisPanelAdditiveDaily.Interpol.5.45 × 10−65.81 × 10281.24 × 1017
7UrinarySpatialAdditiveLM.Cannabis_x_Herb.THC7.84 × 10−152.18 × 10131.14 × 1010
8Posterior Urethral ValveSpatial1 LagLM.Cannabis_x_Herb.THC0.00024.09 × 10181.39 × 109
9Bilateral Renal AgenesisPanelAdditiveDaily.Interpol.0.00031.21 × 10171.95 × 108
10HydronephrosisPanelInteractiveHerb1.75 × 10−73.51 × 1092.01 × 106
11UrinaryPanelAdditiveLM.Cannabis_x_Herb.THC1.91 × 10−56.69 × 1081.22 × 105
12Multicystic Renal DiseasePanel2 LagsDaily.Interpol.0.04331.18 × 101031.15 × 105
13HydronephrosisSpatialAdditiveHerb6.95 × 10−54.51 × 1083.52 × 104
14HydronephrosisPanel2 LagsHerb1.87 × 10−52.33 × 1072.03 × 104
15HydronephrosisSpatialInteractiveHerb0.00056.89 × 1061.46 × 103
16HydronephrosisSpatial1 LagHerb0.00171.23 × 1051258.11
17HydronephrosisPanelAdditiveHerb0.00026.62 × 104303.56
18UrinarySpatialInteractiveDaily.Interpol.0.02445.96 × 1017285.07
19Multicystic Renal DiseaseSpatial2 LagsLM.Cannabis_x_Resin.THC7.72 × 10−56.62 × 103119.49
20Posterior Urethral ValveSpatialInteractiveHerb0.00132.73 × 10483.68
21Posterior Urethral ValveSpatialAdditiveHerb0.00132.74 × 10583.66
22Multicystic Renal DiseasePanelInteractiveTobacco: Daily.Interpol.: LM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.00631.61 × 10556.63
23Posterior Urethral ValveSpatialInteractiveLM.Cannabis_x_Resin.THC_x_Daily.Interpol.8.82 × 10-5955.3243.52
24Posterior Urethral ValveSpatialAdditiveLM.Cannabis_x_Resin.THC_x_Daily.Interpol.8.82 × 10−5954.9543.51
25Bilateral Renal AgenesisPanel2 LagsLM.Cannabis_x_Resin.THC4.60 × 10−1542.8122.36
26Posterior Urethral ValvePanelInteractiveLM.Cannabis_x_Resin.THC2.66 × 10−1043.5617.85
27Multicystic Renal DiseasePanelInteractiveDaily.Interpol.0.04986.23 × 106313.74
28HydronephrosisSpatialInteractiveTobacco: Daily.Interpol.0.0004161.3113.62
29Multicystic Renal DiseasePanelAdditiveLM.Cannabis_x_Resin.THC2.61 × 10−821.289.43
30HydronephrosisPanelInteractiveResin0.0046273.009.28
31Bilateral Renal AgenesisSpatial2 LagsLM.Cannabis_x_Resin.THC0.0023162.579.09
32Multicystic Renal DiseasePanel2 LagsLM.Cannabis_x_Resin.THC0.0097606.018.35
33HydronephrosisSpatialAdditiveDaily.Interpol.0.002682.567.02
34Posterior Urethral ValvePanelAdditiveLM.Cannabis_x_Resin.THC_x_Daily.Interpol.2.25 × 10−710.525.47
35Posterior Urethral ValveSpatial1 LagLM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.0114252.915.45
36Bilateral Renal AgenesisSpatialInteractiveLM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.02283540.005.18
37UrinaryPanelInteractiveLM.Cannabis_x_Resin.THC0.007967.004.73
38Posterior Urethral ValveSpatial2 LagsLM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.0217365.383.75
39UrinarySpatialInteractiveTobacco: LM.Cannabis_x_Resin.THC_x_Daily.Interpol.3.07 × 10−95.013.38
40UrinaryPanelAdditiveLM.Cannabis_x_Herb.THC_x_Daily.Interpol.0.00129.033.23
41HydronephrosisPanelAdditiveLM.Cannabis_x_Herb.THC_x_Daily.Interpol.0.00047.243.13
42HydronephrosisPanelInteractiveLM.Cannabis_x_Herb.THC_x_Daily.Interpol.0.004011.73.06
43Multicystic Renal DiseasePanel2 LagsLM.Cannabis_x_Herb.THC_x_Daily.Interpol.0.026959.952.51
44UrinaryPanelInteractiveLM.Cannabis_x_Herb.THC_x_Daily.Interpol.0.016515.852.38
45UrinarySpatial1 LagLM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.01308.582.10
46Posterior Urethral ValvePanelInteractiveLM.Cannabis_x_Resin.THC_x_Daily.Interpol.3.38 × 10−62.652.02
47UrinaryPanel2 LagsTobacco: Resin6.32 × 10−52.862.02
48Posterior Urethral ValvePanel2 LagsDaily.Interpol.: LM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.048181500.001.89
49Bilateral Renal AgenesisPanelAdditiveResin0.02736.581.62
50Multicystic Renal DiseaseSpatialAdditiveLM.Cannabis_x_Resin.THC0.03109.681.60
51Multicystic Renal DiseaseSpatialInteractiveLM.Cannabis_x_Resin.THC0.03109.681.60
The E-values may be extracted alone and listed and ordered as shown in Table 10. Here, it is noted that 45/51 (88.2%) E-value estimates exceed 9 and are thus in the high range [110], and all 51/51 (100%) exceed the threshold of causality at 1.25 [109]. Moreover, 31/51 (60.8%) mEV’s exceed nine and therefore fall into the high range and 51/51 (100%) exceed the threshold for causality.
Table 9 may also be ordered by anomaly as shown in Table 11 and summarized in Table 12. Table 12 is also ordered by descending median minimum E-value. The table is headed up by hydronephrosis and posterior urethral valve. It is noted that the median mEV’s are relatively high for the five anomalies studied.
Table 9 may also be ordered by the regression term and grouped according to the major covariate between daily cannabis use, and the THC concentration of cannabis herb and resin. This is defined by the extra column which has now been added headed “Group” in Table 13. This table may then be summarized by the primary cannabis metric as shown in Table 14.
These results may then be compared using the Wilcoxson test a indicated in Table 15. One notes immediately that most of the apparent between group differences noted in Table 14 are statistically highly significantly different.
Table 11. E-Values by Anomaly.
Table 11. E-Values by Anomaly.
No.AnomalyRegressionModel TypeTermp-ValueE-Value EstimateLower Bound E-Value
1Bilateral Renal AgenesisPanelInteractiveDaily.Interpol.5.10 × 10−83.41 × 101223.30 × 1081
2Bilateral Renal AgenesisPanelAdditiveDaily.Interpol.0.00031.21 × 10171.95 × 108
3Bilateral Renal AgenesisPanel2 LagsLM.Cannabis_x_Resin.THC4.60 × 10−1542.8122.36
4Bilateral Renal AgenesisSpatial2 LagsLM.Cannabis_x_Resin.THC0.0023162.579.09
5Bilateral Renal AgenesisSpatialInteractiveLM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.02283540.005.18
6Bilateral Renal AgenesisPanelAdditiveResin0.02736.581.62
7HydronephrosisPanelInteractiveDaily.Interpol.0.00381.45 × 10911.36 × 1031
8HydronephrosisPanelAdditiveDaily.Interpol.5.45 × 10-65.81 × 10281.24 × 1017
9HydronephrosisPanelInteractiveHerb1.75 × 10−73.51 × 1092.01 × 106
10HydronephrosisSpatialAdditiveHerb6.95 × 10−54.51 × 1083.52 × 104
11HydronephrosisPanel2 LagsHerb1.87 × 10−52.33 × 1072.03 × 104
12HydronephrosisSpatialInteractiveHerb0.00056.89 × 1061.46 × 103
13HydronephrosisSpatial1 LagHerb0.00171.23 × 1051258.11
14HydronephrosisPanelAdditiveHerb0.00026.62 × 104303.56
15HydronephrosisSpatialInteractiveTobacco: Daily.Interpol.0.0004161.3113.62
16HydronephrosisPanelInteractiveResin0.0046273.009.28
17HydronephrosisSpatialAdditiveDaily.Interpol.0.002682.567.02
18HydronephrosisPanelAdditiveLM.Cannabis_x_Herb.THC_x_Daily.Interpol.0.00047.243.13
19HydronephrosisPanelInteractiveLM.Cannabis_x_Herb.THC_x_Daily.Interpol.0.004011.73.06
20Multicystic Renal DiseaseSpatial2 LagsDaily.Interpol.0.00156.01 × 10671.67 × 1026
21Multicystic Renal DiseasePanel2 LagsDaily.Interpol.0.04331.18 × 101031.15 × 105
22Multicystic Renal DiseaseSpatial2 LagsLM.Cannabis_x_Resin.THC7.72 × 10−56.62 × 103119.49
23Multicystic Renal DiseasePanelInteractiveTobacco: Daily.Interpol.: LM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.00631.61 × 10556.63
24Multicystic Renal DiseasePanelInteractiveDaily.Interpol.0.04986.23 × 106313.74
25Multicystic Renal DiseasePanelAdditiveLM.Cannabis_x_Resin.THC2.61 × 10−821.289.43
26Multicystic Renal DiseasePanel2 LagsLM.Cannabis_x_Resin.THC0.0097606.018.35
27Multicystic Renal DiseasePanel2 LagsLM.Cannabis_x_Herb.THC_x_Daily.Interpol.0.026959.952.51
28Multicystic Renal DiseaseSpatialAdditiveLM.Cannabis_x_Resin.THC0.03109.681.60
29Multicystic Renal DiseaseSpatialInteractiveLM.Cannabis_x_Resin.THC0.03109.681.60
30Posterior Urethral ValveSpatial1 LagDaily.Interpol.0.00095.23 × 10721.08 × 1030
31Posterior Urethral ValveSpatial1 LagLM.Cannabis_x_Herb.THC0.00024.09 × 10181.39 × 109
32Posterior Urethral ValveSpatialInteractiveHerb0.00132.73 × 10483.68
33Posterior Urethral ValveSpatialAdditiveHerb0.00132.74 × 10583.66
34Posterior Urethral ValveSpatialInteractiveLM.Cannabis_x_Resin.THC_x_Daily.Interpol.8.82 × 10−5955.3243.52
35Posterior Urethral ValveSpatialAdditiveLM.Cannabis_x_Resin.THC_x_Daily.Interpol.8.82 × 10−5954.9543.51
36Posterior Urethral ValvePanelInteractiveLM.Cannabis_x_Resin.THC2.66 × 10−1043.5617.85
37Posterior Urethral ValvePanelAdditiveLM.Cannabis_x_Resin.THC_x_Daily.Interpol.2.25 × 10−710.525.47
38Posterior Urethral ValveSpatial1 LagLM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.0114252.915.45
39Posterior Urethral ValveSpatial2 LagsLM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.0217365.383.75
40Posterior Urethral ValvePanelInteractiveLM.Cannabis_x_Resin.THC_x_Daily.Interpol.3.38 × 10−62.652.02
41Posterior Urethral ValvePanel2 LagsDaily.Interpol.: LM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.048181500.001.89
42UrinarySpatialInteractiveLM.Cannabis_x_Herb.THC_x_Daily.Interpol.: LM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.00013.34 × 10474.98 × 1023
43UrinarySpatialAdditiveLM.Cannabis_x_Herb.THC7.84 × 10−152.18 × 10131.14 × 1010
44UrinaryPanelAdditiveLM.Cannabis_x_Herb.THC1.91 × 10−56.69 × 1081.22 × 105
45UrinarySpatialInteractiveDaily.Interpol.0.02445.96 × 1017285.07
46UrinaryPanelInteractiveLM.Cannabis_x_Resin.THC0.007967.004.73
47UrinarySpatialInteractiveTobacco: LM.Cannabis_x_Resin.THC_x_Daily.Interpol.3.07 × 10−95.013.38
48UrinaryPanelAdditiveLM.Cannabis_x_Herb.THC_x_Daily.Interpol.0.00129.033.23
49UrinaryPanelInteractiveLM.Cannabis_x_Herb.THC_x_Daily.Interpol.0.016515.852.38
50UrinarySpatial1 LagLM.Cannabis_x_Resin.THC_x_Daily.Interpol.0.01308.582.10
51UrinaryPanel2 LagsTobacco: Resin6.32 × 10−52.862.02
Table 12. Summary of E-Values by Anomaly.
Table 12. Summary of E-Values by Anomaly.
AnomalyNumberMean Minimum E-ValueMedian Minimum E-ValueMin Minimum E-ValueMax Minimum E-ValueMean E-Value EstimateMedian E-Value EstimateMin E-Value EstimateMax E-Value Estimate
Hydronephrosis131.05 × 10301258.113.061.36 × 10311.12 × 10901.23 × 1057.241.45 × 1091
Posterior Urethral Valve129.00 × 102830.681.891.08 × 10304.36 × 1071955.142.655.23 × 1072
Bilateral Renal Agenesis65.50 × 108015.731.623.30 × 10815.68 × 101211.85 × 1036.583.41 × 10122
Multicystic Renal Disease101.67 × 102511.591.61.67 × 10261.18 × 101023.61 × 1039.681.18 × 10103
Urinary104.98 × 10224.0552.024.98 × 10233.34 × 104641.432.863.34 × 1047
Table 13. E-Values by Covariate.
Table 13. E-Values by Covariate.
No.AnomalyRegressionModel TypeTermGroupp-ValueE-Value EstimateLower Bound E-Value
1Bilateral Renal AgenesisPanelInteractiveDaily.Interpol.Daily5.10 × 10−83.41 × 101223.30 × 1081
2HydronephrosisPanelInteractiveDaily.Interpol.Daily0.00381.45 × 10911.36 × 1031
3Posterior Urethral ValveSpatial1 LagDaily.Interpol.Daily0.00095.23 × 10721.08 × 1030
4Multicystic Renal DiseaseSpatial2 LagsDaily.Interpol.Daily0.00156.01 × 10671.67 × 1026
5HydronephrosisPanelAdditiveDaily.Interpol.Daily5.45 × 10−65.81 × 10281.24 × 1017
6Bilateral Renal AgenesisPanelAdditiveDaily.Interpol.Daily0.00031.21 × 10171.95 × 108
7Multicystic Renal DiseasePanel2 LagsDaily.Interpol.Daily0.04331.18 × 101031.15 × 105
8UrinarySpatialInteractiveDaily.Interpol.Daily0.02445.96 × 1017285.07
9Multicystic Renal DiseasePanelInteractiveDaily.Interpol.Daily0.04986.23 × 106313.74
10HydronephrosisSpatialAdditiveDaily.Interpol.Daily0.002682.567.02
11Posterior Urethral ValvePanel2 LagsDaily.Interpol.: LM.Cannabis_x_Resin.THC_x_Daily.Interpol.Daily0.048181500.001.89
12HydronephrosisPanelInteractiveHerbHerb1.75 × 10−73.51 × 1092.01 × 106
13HydronephrosisSpatialAdditiveHerbHerb6.95 × 10−54.51 × 1083.52 × 104
14HydronephrosisPanel2 LagsHerbHerb1.87 × 10−52.33 × 1072.03 × 104
15HydronephrosisSpatialInteractiveHerbHerb0.00056.89 × 1061.46 × 103
16HydronephrosisSpatial1 LagHerbHerb0.00171.23 × 1051258.11
17HydronephrosisPanelAdditiveHerbHerb0.00026.62 × 104303.56
18Posterior Urethral ValveSpatialInteractiveHerbHerb0.00132.73 × 10483.68
19Posterior Urethral ValveSpatialAdditiveHerbHerb0.00132.74 × 10583.66
20UrinarySpatialAdditiveLM.Cannabis_x_Herb.THCHerb7.84 × 10−152.18 × 10131.14 × 1010
21Posterior Urethral ValveSpatial1 LagLM.Cannabis_x_Herb.THCHerb0.00024.09 × 10181.39 × 109
22UrinaryPanelAdditiveLM.Cannabis_x_Herb.THCHerb1.91 × 10−56.69 × 1081.22 × 105
23UrinaryPanelAdditiveLM.Cannabis_x_Herb.THC_x_Daily.Interpol.Herb0.00129.033.23
24HydronephrosisPanelAdditiveLM.Cannabis_x_Herb.THC_x_Daily.Interpol.Herb0.00047.243.13
25HydronephrosisPanelInteractiveLM.Cannabis_x_Herb.THC_x_Daily.Interpol.Herb0.004011.73.06
26Multicystic Renal DiseasePanel2 LagsLM.Cannabis_x_Herb.THC_x_Daily.Interpol.Herb0.026959.952.51
27UrinaryPanelInteractiveLM.Cannabis_x_Herb.THC_x_Daily.Interpol.Herb0.016515.852.38
28UrinarySpatialInteractiveLM.Cannabis_x_Herb.THC_x_Daily.Interpol.: LM.Cannabis_x_Resin.THC_x_Daily.Interpol.Herb0.00013.34 × 10474.98 × 1023
29Multicystic Renal DiseaseSpatial2 LagsLM.Cannabis_x_Resin.THCResin7.72 × 10−56.62 × 103119.49
30Bilateral Renal AgenesisPanel2 LagsLM.Cannabis_x_Resin.THCResin4.60 × 10−1542.8122.36
31Posterior Urethral ValvePanelInteractiveLM.Cannabis_x_Resin.THCResin2.66 × 10−1043.5617.85
32Multicystic Renal DiseasePanelAdditiveLM.Cannabis_x_Resin.THCResin2.61 × 10−821.289.43
33Bilateral Renal AgenesisSpatial2 LagsLM.Cannabis_x_Resin.THCResin0.0023162.579.09
34Multicystic Renal DiseasePanel2 LagsLM.Cannabis_x_Resin.THCResin0.0097606.018.35
35UrinaryPanelInteractiveLM.Cannabis_x_Resin.THCResin0.007967.004.73
36Multicystic Renal DiseaseSpatialAdditiveLM.Cannabis_x_Resin.THCResin0.03109.681.60
37Multicystic Renal DiseaseSpatialInteractiveLM.Cannabis_x_Resin.THCResin0.03109.681.60
38Posterior Urethral ValveSpatialInteractiveLM.Cannabis_x_Resin.THC_x_Daily.Interpol.Resin8.82 × 10−5955.3243.52
39Posterior Urethral ValveSpatialAdditiveLM.Cannabis_x_Resin.THC_x_Daily.Interpol.Resin8.82 × 10−5954.9543.51
40Posterior Urethral ValvePanelAdditiveLM.Cannabis_x_Resin.THC_x_Daily.Interpol.Resin2.25 × 10−710.525.47
41Posterior Urethral ValveSpatial1 LagLM.Cannabis_x_Resin.THC_x_Daily.Interpol.Resin0.0114252.915.45
42Bilateral Renal AgenesisSpatialInteractiveLM.Cannabis_x_Resin.THC_x_Daily.Interpol.Resin0.02283540.005.18
43Posterior Urethral ValveSpatial2 LagsLM.Cannabis_x_Resin.THC_x_Daily.Interpol.Resin0.0217365.383.75
44UrinarySpatial1 LagLM.Cannabis_x_Resin.THC_x_Daily.Interpol.Resin0.01308.582.10
45Posterior Urethral ValvePanelInteractiveLM.Cannabis_x_Resin.THC_x_Daily.Interpol.Resin3.38 × 10−62.652.02
46HydronephrosisPanelInteractiveResinResin0.0046273.009.28
47Bilateral Renal AgenesisPanelAdditiveResinResin0.02736.581.62
48HydronephrosisSpatialInteractiveTobacco: Daily.Interpol.Daily0.0004161.3113.62
49Multicystic Renal DiseasePanelInteractiveTobacco: Daily.Interpol.: LM.Cannabis_x_Resin.THC_x_Daily.Interpol.Resin0.00631.61 × 10+556.63
50UrinarySpatialInteractiveTobacco: LM.Cannabis_x_Resin.THC_x_Daily.Interpol.Resin3.07 × 10−95.013.38
51UrinaryPanel2 LagsTobacco: ResinResin6.32 × 10−52.862.02
Table 14. Summary of E-Values by Major Covariate.
Table 14. Summary of E-Values by Major Covariate.
GroupNumberMean Minimum E-ValueMedian Minimum E-ValueMinimum Minimum E-ValueMaximum Minimum E-ValueMean E-Value EstimateMedian E-Value EstimateMinimum E-Value EstimateMaximum E-Value Estimate
Daily122.75 × 10809.76 × 1071.893.30 × 10812.84 × 101213.12 × 106382.563.41 × 10122
Herb172.93 × 10221258.112.384.98 × 10231.96 × 10462.74 × 1057.243.34 × 1047
Resin2217.205.461.6119.497952.7455.282.651.61 × 105
Table 15. Wilcoxson Tests of Major Group Contrasts.
Table 15. Wilcoxson Tests of Major Group Contrasts.
ComparisonW-StatisticAlternativep-Value
mEV, Daily_v_Herb132two.sided0.1947
mEV, Daily_v_Resin223two.sided0.0011
mEV, Herb_v_Resin292two.sided0.0031
EVEstimate, Daily_v_Herb165two.sided0.0043
EVEstimate, Daily_v_Resin243two.sided6.82 × 10−5
EVEstimate, Herb_v_Resin297two.sided0.0019
Legend: mEV—minimum E-Value; EVEstimate—E-value estimate.

4. Discussion

4.1. Main Results

The main results of this study is that all the UCAR’s identified are closely related to various metrics of cannabis exposure. Strong relationships were demonstrated on bivariate analysis which persisted after multivariable adjustment in inverse probability weighted panel models and thereby fulfilled the formal criteria of quantitative causal inference. These results were also confirmed for all five UCA’s studies by multivariable geospatial regression.

4.2. Detailed Main Results

A mapping analysis demonstrated that UCAR’s increased across Spain, Netherlands, Poland and France. Congenital posterior urethral valve rates increased in Spain, France, Belgium, Poland and Netherlands. Multicystic renal disease increased in Spain, France, Netherlands and Norway. A bivariate map study showed that UCAR’s and last month cannabis use x cannabis resin THC concentration increased simultaneously in France, Spain, Netherlands and Bulgaria. Bilateral renal agenesis increased along with last month cannabis use x cannabis resin THC concentration in Netherlands. Congenital posterior urethral valve increased along with last month cannabis use x cannabis resin THC concentration in Netherlands and France. Multicystic renal disease increased along with last month cannabis use x cannabis resin THC concentration in Netherlands and France. That is UCAR’s increased in countries with increased daily cannabis exposure.
When nations with increasing daily cannabis use were compared with those without the former group has a higher rate of UCA’s overall (p = 0.0073). When this comparison was made by UCA this relationship intensified (p = 8.73 × 10−5).
At bivariate analysis tobacco exposure was not related to UCA’s. Alcohol exposure was related to multicystic renal disease and posterior urethral valve. Cocaine and amphetamine were strongly related to most UCA’s. All UCA’s were strongly related to cannabis herb and resin THC concentrations (Figure 1 and Figure 2). All anomalies could be related to cannabis metrics on bivariate analysis with strength of association judged by the median minimum E-value (mEV) as hypospadias (174.71) > multicystic renal disease (5.37) > bilateral renal agenesis (5.05) > UCA’s (2.68) > hydronephrosis (2.21) > posterior urethral valve (1.73) > bladder exstrophy/epispadias (1.53) (Table 1).
At inverse probability weighted multivariable analysis terms including cannabis were significant for the following series of anomalies: UCA’s, multicystic renal disease, bilateral renal agenesis, hydronephrosis, congenital posterior urethral valves from P = 1.91 × 10−5, 2.61 × 10−8, 4.60 × 10−15, 4.60 × 10−15 and 2.66 × 10−10 (Supplementary Tables S8–S12). At geospatial analysis the same series of UCA’s were significantly related to cannabis from p = 7.84 × 10−15, 7.72 × 10−5, 0.0023, 6.95 × 10−5, and 8.82 × 10−5 (Table 2, Table 3, Table 4, Table 5 and Table 6).
45/51 (88.2%) of E-value estimates and 31/51 (60.8%) of mEV’s exceeded nine and were thus in the high range [110]. 100% of both E-value estimates and mEV’s exceeded the threshold of causality at 1.25 (Table 10) [109]. At multivariable analysis the rank of strength of association was hydronephrosis > posterior urethral valve > bilateral renal agenesis > multicystic renal disease > UCA’s (Table 12). The rank of primary cannabis covariates was daily use > cannabis herb THC concentration > cannabis resin THC concentration (Table 14).

4.3. Choice of Anomalies

The selection of UCA’s chosen for detailed analysis was based upon their implication in prior reports as mentioned in the Introduction, the frequency of the anomaly and the clinical significance. Hypospadias and epispadias were not chosen as they are relatively minor anomalies. Bladder exstrophy was not studied further as it is very rare.

4.4. Qualitative Causal Inference

It is worth considering how the present results perform against the Hill criteria of causality which are accepted criteria for assessing causal relationships [112]. These criteria were strength of association, consistency amongst studies, specificity, temporality, coherence with known data, biological plausibility, overresponse relationship, analogy with similar situations elsewhere and experimental confirmation. It is noted that the present study fulfills all of these criteria.

4.5. Quantitative Causal Inference

One of the major issues confronting the interpretation of observational studies is the issue of non-comparability of experimental groups. This issue can be addressed by inverse probability weighting which is the technique of choice in causal inference and has been widely adopted here in all panel models. This technique has the effect of transforming the analysis from that of an observational study only into a pseudorandomized quasi-experimental system from which it is entirely proper to draw causal inferences.
The other issue with which observational studies are frequently confronted is the potential for some uncontrolled extraneous confounding covariate to explain away the reported results. This issue is addressed by calculating the E-value which quantifies the degree of association required of such an hypothetical covariate with both the exposure of concern and the outcome of interest in order to obviate the reported apparently association. E-Values (expected values) in excess of nine are reported as being in the high range [110] and a cut-ff of 1.25 is usually applied as a threshold of a potentially causal effect [109]. Hence, the very elevated E-values reported in the present study are well above this range and qualify findings to be designated as causal in nature.
Together with highly concordant results reported from several other jurisdictions and the strong theoretical mechanistic basis of these findings the highly significant results reported herein exclude the possibility that the results reported may be due to either chance (p-values) or bias (E-values).

4.6. Mechanisms

As noted in the Introduction cannabinoid genotoxicity is mediated by multiple pathways. These have been reviewed in detail elsewhere [1,2,3,4,5,6,7,8,9,14,15,23,24,25,43,54,55,113,114,115]. For our present purposes however it suffices to consider two main mechanistic classes, inhibition of the major morphogen gradients governing embryological morphogenesis and epigenomic mechanisms.

4.7. Cannabinoid Inhibition of Embryonic Morphogens

Many of the key morphogen gradients governing human embryogenesis are known to be disrupted by cannabinoids including sonic hedgehog [116], fibroblast growth factor [117,118], bone morphogenetic proteins [119,120,121] and retinoic acid [122,123,124].
In part this effects happens directly but it is also partly epigenomically mediated. Hence, for example genes such as GLI3, (Gli family zinc finger 3), MEGF8 (multiple EGF-like domains 8), TMEM107 (transmembrane protein 107) and BMP4 (bone morphogenetic protein 4) which are frequently cited in the epigenome-wide screen as being altered in cannabis dependence and withdrawal, are known to function in or around or antagonize sonic hedgehog signalling which is a critically important controller of embryonic morphogenesis across numerous tissues and organs.

4.8. Epigenomic Control of Uronephrological Gene Expression

Review of the supplementary material supplied in the recent epigenome-wide DNA methylation screen of Schrott and colleagues in both cannabis dependence and withdrawal [55] shows identified functional annotations on an Ingenuity Pathway Screen for renal agenesis (5 genes, page 311 in cannabis dependence), morphology of the renal tubule (8 genes, page 313), urinary tract cancer (84 genes, page 320), renal morphology (16 genes, page 322, p = 0.00216; 17 genes, p = 0.0022, page 322), formation of renal lesions (48 genes, page 322), abnormalities of the renal tubule (7 genes, page 323), congenital anomalies of the kidneys and urinary tract (9 genes, page 351 in cannabis withdrawal) and familial congenital anomalies of the kidney and urinary tract (8 genes, page 352; see Table 16).
Genes involved in male genital neoplasia were also notable increased (153 genes, page 279, p = 1.14 × 10−8; 151 genes, p = 1.60 × 10−9, page 279) and (60 genes, page 341 in cannabis withdrawal).
Functional annotations applicable to prostatic neoplasia were also identified (148 genes, page 279, p = 2.88 × 10−8 in cannabis dependence; 60 genes, page 341, p = 0.000675 in cannabis withdrawal; 59 genes, page 340, p = 0.000533), and adhesion of prostate cancer cells (1 gene, page 357, p = 0.00701, EPHA2).
This link between cannabidiol and prostate cancer has been confirmed in recent epidemiological reports [1,2,3].
Female genital neoplasia was also linked by functional annotations including female genital adenocarcinoma (197 genes, page 272, p = 1.84 × 10−11 in cannabis dependence; 2.05 × 10−11, 215 genes, page 273; 216 genes, page 276, p = 8.95 × 10−11) and female genital tract cancer (78 genes, page 349 in cannabis withdrawal, p = 0.00303) and female genital neoplasm (79 genes, page 350). Breast and ovarian cancer were identified together by related sets of genes (133 genes, page 315, p = 0.000965 in cannabis dependence; 121 genes page 121, p = 0.000161).
This link between cannabidiol and ovarian cancer was confirmed in a recent epidemiological study [1,2,3].

4.9. Nephrogenic Genes in Renal Organoids

A recent detailed study of renal morphogenesis has been most revealing in terms of disclosing, and confirming genes critically involved in renal morphogenesis [125]. Inhibition of ROCK (Rho associated coiled-coil containing protein kinase) proved to be a key step in dramatically increasing the yield of embryonic stem cell differentiation into nephroblastic progenitor cells. Many genes involved in the induction of ciliopathies were also implicated in grossly abnormal nephrogenesis. Furthermore, the key notch ligand Jag1 (Jagged canonical notch ligand) was shown to potently inhibit differentiation into renal tubular cells.
Table 17 lists several of the genes from the notch pathway which were identified in the epigenomic EWAS of Schrott and colleagues [55]. RBPJ (Recombination Signal Binding Protein for Immunoglobulin Kappa J Region) and PSENEN (Presenilin enhancer, gamma secretase subunit, a key transmembrane effector of notch ligand cleavage and thus signal transduction) were prominently identified as shown.
Sonic hedgehog (shh) is another key morphogen involved in nephrogenesis [125,126]. Table 18 lists some of the EWAS hits from the Schrott study where shh pathway members were identified as being disrupted by cannabis exposure. Patched is the canonical shh receptor. SUFU (SUFU negative regulator of hedgehog signalling) is an inhibitor, PSENEN also cleaves the shh ligand at the cell membrane and Gli3 (GLI family zinc finger 3) is a key DNA binding transcription factor of the shh pathway. As there were 185 EWAS hits for Gli3 only a sample can been displayed in the table.
Table 19 provides a further list of key genes involved in nephrogenesis. The CCDC genes are coiled-coil domain containing proteins. CCDC170 was noted to be key for renal tubule cell formation as was MYH7 (Myosin heavy chain 7) and EPCAM (epithelial cell adhesion molecule), the bone morphogenetic proteins (BMP’s) and the Wnt’s. Indeed the Schrott data included 191 hits for BMP’s and 203 hits for Wnt family members.
Table 17. EWAS Hits from Schrott Dataset for Significantly Differentially Methylated Regions for.Notch Signalling.
Table 17. EWAS Hits from Schrott Dataset for Significantly Differentially Methylated Regions for.Notch Signalling.
Nearest Gene NameChromosome NumberNearest Gene NumberDependency StatusFunctional AnnotationPageDistance from Nearest GeneRelative Positionp-ValueBonferroni Adjusted p-Value
JAG120ENSG00000101384DependenceNotch Ligand360Intron1.31 × 10−60.007992
NOTCH21ENSG00000134250DependenceNotch Pathway550Intron3.07 × 10−60.007992
NOTCH19ENSG00000101384DependenceNotch Pathway560Intron3.29 × 10−60.012443
NOTCH21ENSG00000134250DependenceNotch Pathway640Intron4.19 × 10−60.013994
NOTCH319ENSG00000074181DependenceNotch Pathway863797Downstream7.65 × 10−60.018677
NOTCH2NLC1ENSG00000286219WithdrawalNotch Pathway1650Intron2.85 × 10−60.012636
RBPJ4ENSG00000168214DependenceNotch Pathway1070Intron1.17 × 10−50.022698
RBPJP29ENSG00000274181DependenceNotch Pathway12119867Upstream1.50 × 10−50.025700
RBPJ4ENSG00000168214WithdrawalNotch Pathway1250Intron1.34 × 10−80.000859
Nearest Gene NameChromosome NumberNearest Gene NumberDependency StatusFunctional AnnotationPageFunctionNumber Genes Identifiedp-Value
PSENEN19ENSG00000205155WithdrawalSkin Lesion325Notch Processing1151.65 × 10−6
PSENEN19ENSG00000205155WithdrawalSkin cancer325Notch Processing1134.79 × 10−6
PSENEN19ENSG00000205155WithdrawalCutaneous melanoma326Notch Processing1107.71 × 10−6
PSENEN19ENSG00000205155WithdrawalSolid Organ cancer327Notch Processing1509.16 × 10−6
PSENEN19ENSG00000205155WithdrawalCancer329Notch Processing1514.32 × 10−5
PSENEN19ENSG00000205155WithdrawalMelanoma329Notch Processing1156.21 × 10−5
PSENEN19ENSG00000205155WithdrawalSolid Organ cancer335Notch Processing1491.63 × 10−4
PSENEN19ENSG00000205155WithdrawalProtein processing353Notch Processing44.69 × 10−3
PSENEN19ENSG00000205155WithdrawalOrganismal death356Notch Processing396.70 × 10−3
Table 18. EWAS Hits from Schrott Dataset for Significantly Differentially Methylated Regions for. Sonic Hedgehog Signalling.
Table 18. EWAS Hits from Schrott Dataset for Significantly Differentially Methylated Regions for. Sonic Hedgehog Signalling.
Nearest Gene NameChromosome NumberNearest Gene NumberDependency StatusFunctional AnnotationPageDistance from Nearest GeneRelative Positionp-ValueBonferroni Adjusted p-Value
PTCH19ENSG00000185920DependenceShh Receptor580Intron3.46 × 10−60.012789
PTCHD1-ASXENSG00000233067Dependencelnc Promoter/enhancer910Intron8.61 × 10−60.019678
PTCHD1-ASXENSG00000233067Withdrawallnc Promoter/enhancer1290Intron8.21 × 10−80.002096
PTCHD46ENSG00000244694WithdrawalShh Receptor; Otopalatodigital syndrome1380Intron4.21 × 10−70.005104
PTCH19ENSG00000185920WithdrawalShh Receptor1850Intron5.80 × 10−60.017679
SUFU16ENSG00000161996WithdrawalHedgehog Inhibitor2070Exon1.01 × 10−50.022942
Gli37ENSG00000106571DependenceShh mediator7881,232Downstream6.35 × 10−60.017090
Gli37ENSG00000106571DependenceShh mediator990Intron1.00 × 10−50.021181
Gli37ENSG00000106571WithdrawalShh mediator12420,318Downstream8.23 × 10−90.000646
Gli37ENSG00000106571WithdrawalShh mediator1820Intron5.28 × 10−60.001687
Gli37ENSG00000106571WithdrawalShh mediator2310Intron1.62 × 10−50.028539
Nearest Gene NameChromosome NumberNearest Gene NumberDependency StatusFunctional AnnotationPageFunctionNumber Genes Identifiedp-Value
PTCH19ENSG00000185920KEGG PathwayNotch Processing237Notch Processing310.044117
PTCH19ENSG00000185920KEGG PathwaySkin cancer238Notch Processing540.067770
PSENEN19ENSG00000185920WithdrawalCutaneous melanoma326Notch Processing1100.000008
Gli37ENSG00000106571WithdrawalSkin lesion325Notch TF1151.65 × 10−6
Gli37ENSG00000106571WithdrawalHead & Neck SCC325Notch TF533.59 × 10−6
Gli37ENSG00000106571WithdrawalSkin cancer325Notch TF1134.79 × 10−6
Gli37ENSG00000106571WithdrawalLung adenocarcinoma325Notch TF425.84 × 10−6
Gli37ENSG00000106571WithdrawalCancer325Notch TF1497.17 × 10−6
Gli37ENSG00000106571WithdrawalLarge bowel cancer326Notch TF1207.45 × 10−6
Gli37ENSG00000106571WithdrawalCutaneous melanoma326Notch TF1107.71 × 10−6
Gli37ENSG00000106571WithdrawalHighg grade astrocytoma326Notch TF828.42 × 10−6
Gli37ENSG00000106571WithdrawalAbdominal adenocarcinoma326Notch TF1358.46 × 10−6
Gli37ENSG00000106571WithdrawalSolid cancer327Notch TF1509.16 × 10−6
Gli37ENSG00000106571WithdrawalHaed and Neck cancer327Notch TF1379.54 × 10−6
Gli37ENSG00000106571WithdrawalSensory development327Notch TF181.30 × 10−5
Gli37ENSG00000106571WithdrawalCarcinoma327Notch TF1481.38 × 10−5
Table 19. EWAS Hits from Schrott Dataset for Significantly Differentially Methylated Regions for. Major Genes of Nephrogenesis I.
Table 19. EWAS Hits from Schrott Dataset for Significantly Differentially Methylated Regions for. Major Genes of Nephrogenesis I.
Nearest Gene NameChromosome NumberNearest Gene NumberDependency StatusFunctional AnnotationPageDistance from Nearest GeneRelative Positionp-ValueBonferroni Adjusted p-Value
CCDC17818ENSG00000166960DependenceCoiled coil domain containing210Intron3.78 × 10−70.004344
CCDC17818ENSG00000166960DependenceCoiled coil domain containing470Intron2.29 × 10−60.010512
CCDC1719ENSG00000164989DependenceCoiled coil domain containing530Intron2.88 × 10−60.011635
CCDC17818ENSG00000166960DependenceCoiled coil domain containing1190Intron1.46 × 10−50.025394
CCDC1719ENSG00000164989WithdrawalCoiled coil domain containing3590Intron8.36 × 10−80.002109
CCDC1706ENSG00000120262WithdrawalCoiled coil domain containing1360Intron3.29 × 10−70.004420
CCDC17514ENSG00000151838WithdrawalCoiled coil domain containing1480Intron1.11 × 10−60.008146
CCDC1719ENSG00000164989WithdrawalCoiled coil domain containing16957,410Downstream3.38 × 10−60.013764
CCDC1719ENSG00000164989WithdrawalCoiled coil domain containing1700Intron3.50 × 10−60.139199
CCDC17818ENSG00000166960WithdrawalCoiled coil domain containing1860Intron5.94 × 10−60.017905
CCDC1719ENSG00000164989WithdrawalCoiled coil domain containing1890Intron6.67 × 10−60.019063
CCDC1719ENSG00000164989WithdrawalCoiled coil domain containing2030Intron9.26 × 10−60.022131
MYH714ENSG00000092054DependenceMyosin heavy chain 7B8112,605Upstream6.91 × 10−60.017781
ROCK118ENSG00000067900DependenceRho associated Coiled Coil Kinase202,527,461Downstream3.17 × 10−70.003991
ROCK118ENSG00000067900DependenceRho associated Coiled Coil Kinase200Intron5.41 × 10−60.015884
ROCK118ENSG00000067900DependenceRho associated Coiled Coil Kinase20411,279Downstream4.72 × 10−60.016044
EPCAM-DT2ENSG00000234690DependenceEpithelial Cell adhesion molecule—divergent transcript2210Intron1.33 × 10−50.025950
BMPR21ENSG00000204217DependenceBMP Receptor 2120Intron8.38 × 10−80.001951
BMPR1B4ENSG00000138696DependenceBMP Receptor 1B250Intron5.68 × 10−70.005306
BMPR24ENSG00000138696DependenceBMP Receptor 1B350Intron1.22 × 10−60.007711
BMPER7ENSG00000164619DependenceBMP Endothelial regulator420Intron1.83 × 10−60.009422
BMP66ENSG00000153162DependenceBMP 6560Intron3.18 × 10−60.012217
BMPR1B4ENSG00000138696DependenceBMP Receptor 1B700Intron5.19 × 10−60.015541
BMPR1A10ENSG00000107779DependenceBMP Receptor 1A960Intron9.50 × 10−60.020621
BMPR1B4ENSG00000138696DependenceBMP Receptor 1B980Intron9.94 × 10−60.021066
BMPER7ENSG00000164619DependenceBMP Endothelial regulator1130Intron1.32 × 10−50.024145
BMPR1B4ENSG00000138696WithdrawalBMP Receptor 1B1240Intron7.92 × 10−90.000631
WNT7B22ENSG00000188064DependenceWnt family member 7B740Intron5.78 × 10−60.016375
WNT7B22ENSG00000188064WithdrawalWnt family member 7B1610Intron2.38 × 10−60.011749
WNT7A3ENSG00000154764DependenceWnt family member 7A1190Intron1.47 × 10−50.025468
WNT7A3ENSG00000154764WithdrawalWnt family member 7A1230Intron4.13 × 10−90.000453
WNT27ENSG00000105989DependenceWnt family member 2260Intron1.02 × 10−60.007849
WNT5A3ENSG00000114251WithdrawalWnt family member 5A15026,665Downstream1.25 × 10−60.008600
WNT7A3ENSG00000154764DependenceWnt family member 7A15013,677Upstream1.27 × 10−60.008678
WNT7B22ENSG00000188064WithdrawalWnt family member 7B1610Intron2.38 × 10−60.011749
WNT9B17ENSG00000158955WithdrawalWnt family member 9B2110Intron1.10 × 10−50.023817
WNT167ENSG00000002745WithdrawalWnt family member 162270Intron1.50 × 10−50.027474
Some of the hits for the Wnt’s are listed in Table 20 and their very high level of statistical significance is evident.
Table 21 lists some of the Schrott EWAS hits for ROCK1.
TGFβ was also shown to be important in the renal organoid GWAS screen and induced interstitial fibrosis in line with its well known activities in many other tissues. Eight EWAS hits from the Schrott data for TGFβ are shown in Table 22. Downstream TGFβ signals are transduced by a cascade of SMAD (mothers against decapentaplegic homologue) intermediates and transcription factors. SMAD4 is the final transcription factor to enter the nucleus from this pathway. Cannabis exposure EWAS hits for this series of mediators is also shown in the table.

4.10. Exponential Genotoxic Effects

A wide variety of studies have documented the exponential dose–response relationship of mutagenicity and various indices of cannabinoids exposure [43,65,66,67,68,69,70,71,72,73,74,75,76,77,78]. This applies both to directly genotoxic studies and to studies of the intermediary mitochondrial metabolism upon which genomic and epigenomic reactions are based both as substrates and for energy supply. Moreover, several reports confirm that the exponential effects seen in the laboratory are also documented in patterns of human disease, particularly by modelling studies and by showing an abrupt discontinuous step in disease rates from the fourth to the faith quintile of cannabinoid exposure.
This exponential cannabinoid dose–response relationship where disease rates occur at higher levels of cannabinoid exposure is very important when interpreting epidemiological patterns of UCAR’s. This is especially so for Europe where increases in cannabis use prevalence, cannabis use daily intensity, and THC concentration in cannabis herb and resin are all going on at the same time creating an exponential cannabinoid exposure curve. This in turn implies that whole nations can be relatively suddenly moved up into the genotoxic dose–response zone where major and severe genotoxic outcomes become commonplace. As was noted this may account for severe and apparently abrupt teratological outbreaks such as the limblessness phenomena described earlier.

4.11. Strengths and Limitations

This study has many strengths including the use of one of the largest UCAR databases in the world and the very comprehensive EMCDDA drug dataset. Moreover, advanced statistical modelling has been utilized in performing this analysis including inverse probability weighting, lagged models, the formal tools of quantitative causal inference and geospatiotemporal regression modelling. Panelled maps and graphs have been used to show all covariates across time at a single glace. Bivariate maps have also been used, which is unusual. Moreover, a sophisticate mechanistic understanding has been presented which not only explains the pattern of UCAR’s observed but contributes pivotal information into the key issue of causal assignment. Study limitations include the lack of individual participant exposure information, a limitation which is shared in common with many epidemiological investigations. Moreover, missing data was an issue form some covariates particularly daily cannabis use and this must be borne in mind in considering the present results.

4.12. Generalizability

Results of this study are widely generalizable for several reasons. The analysis is based on one of the largest UCAR datasets in the world, and concordant with similar published results presented from other jurisdictions. Further, results are at high levels statistical significance and sensitivity analysis using E-values indicates that they are robust to extraneous explanations. Moreover, the analysis has been conducted within a formal quantitative causal inferential framework so that the effects demonstrated may be designated as causal effects. For all of these reasons we feel that these results are widely generalizable to other situations wherever data of sufficient quality exist to make the relevant assessments.

5. Conclusions

In conclusion this analysis confirms previous reports showing that many UCA’s are related to various metrics of cannabis exposure. To those anomalies which have already been described this report adds congenital hydronephrosis, multicystic renal disease and urinary anomalies overall as newly cannabis associated congenital anomalies. This analysis has been conducted within a causal inferential framework including the use of inverse probability weighting and E-values which formally demonstrate that the quantitative criteria of formal causal inference are fulfilled. Particular concern applies to the relatively rapid rise of many parts of Europe into the higher dose cannabinoid exposure zone including by contamination of the food chain where major genotoxic outcomes become commonplace. As discussed there is some evidence that this may be occurring in parts of France and Germany already. Another major and related corollary is real concern for multigenerational damage to the epigenome. Evidence presented indicates that epigenomic explanations may well underlie many of the effects observed and the potential for transgenerational transmission of epigenomic effects is very real and of great concern. Such issues, together with the robust and causal relationships demonstrated in the present investigation indicate that community cannabinoid penetration should be carefully and closely constrained and restricted and appropriate protections must be put in place for protection of the food chain and the genomes and epigenomes of generations yet to come.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijerph192113769/s1, Figure S1: Geospatial Links; Table S1: Overall Study Profile; Table S2, Daily Cannabis Use—Raw Data; Table S3: Daily Cannabis Use—Interpolated Data; Table S4: All regression slopes and results from bivariate analyses; Table S5: Variable Importance Tables from Ranger random forest regression—Uronephrological anomalies; Table S6: Variable Importance Tables from Ranger random forest regression—Multicystic renal disease; Table S7: Variable Importance Tables from Ranger random forest regression—Bilateral renal agenesis; Table S8: Variable Importance Tables from Ranger random forest regression—Hydronephrosis; Table S9: Variable Importance Tables from Ranger random forest regression—Congenital posterior urethral valve; Table S10: Inverse probability weighted panel regression results—Uronephrological anomalies; Table S11: Inverse probability weighted panel regression results—Multicystic renal disease; Table S12: Inverse probability weighted panel regression results—Bilateral renal agenesis; Table S13: Inverse probability weighted panel regression results—Hydronephrosis; Table S14: Inverse probability weighted panel regression results—Congenital posterior urethral valve.

Author Contributions

A.S.R. assembled the data, designed and conducted the analyses, and wrote the first manuscript draft. G.K.H. provided technical and logistic support, co-wrote the paper, assisted with gaining ethical approval, provided advice on manuscript preparation and general guidance to study conduct. A.S.R. had the idea for the article, performed the literature search, wrote the first draft and is the guarantor for the article. All authors have read and agreed to the published version of the manuscript.

Funding

No funding was provided for this study. No funding organization played any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Institutional Review Board Statement

The Human Research Ethics Committee of the University of Western Australia provided ethical approval for the study to be undertaken 24 September 2021 (No. RA/4/20/4724).

Informed Consent Statement

Patient consent was waived due to all data being publicly available, anonymous and grouped. No identifiable data was accessed used, employed or published.

Data Availability Statement

All data generated or analysed during this study are included in this published article and its Supplementary Information Files. Data along with the relevant R code has been made publicly available on the Mendeley Database Repository and can be accessed from these URL’s: https://data.mendeley.com/datasets/c6psrbr34j/2 (accessed on 1 February 2022) and https://data.mendeley.com/datasets/vd6mt5r5jm/1 (accessed on 1 February 2022).

Acknowledgments

All authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Conflicts of Interest

The authors declare that they have no competing interests.

References

  1. Reece, A.S.; Hulse, G.K. Geotemporospatial and Causal Inferential Epidemiological Overview and Survey of USA Cannabis, Cannabidiol and Cannabinoid Genotoxicity Expressed in Cancer Incidence 2003–2017: Part 1–Continuous Bivariate Analysis. Arch. Public Health 2022, 80, 99–133. [Google Scholar] [CrossRef] [PubMed]
  2. Reece, A.S.; Hulse, G.K. Geotemporospatial and Causal Inferential Epidemiological Overview and Survey of USA Cannabis, Cannabidiol and Cannabinoid Genotoxicity Expressed in Cancer Incidence 2003–2017: Part 2–Categorical Bivariate Analysis and Attributable Fractions. Arch. Public Health 2022, 80, 100–135. [Google Scholar] [CrossRef] [PubMed]
  3. Reece, A.S.; Hulse, G.K. Geotemporospatial and Causal Inferential Epidemiological Overview and Survey of USA Cannabis, Cannabidiol and Cannabinoid Genotoxicity Expressed in Cancer Incidence 2003–2017: Part 3–Spatiotemporal, Multivariable and Causal Inferential Pathfinding and Exploratory Analyses of Prostate and Ovarian Cancers. Arch. Public Health 2022, 80, 100–136. [Google Scholar]
  4. Reece, A.S.; Hulse, G.K. Cannabinoid exposure as a major driver of pediatric acute lymphoid Leukaemia rates across the USA: Combined geospatial, multiple imputation and causal inference study. BMC Cancer 2021, 21, 984–1017. [Google Scholar] [CrossRef]
  5. Reece, A.S.; Hulse, G.K. A geospatiotemporal and causal inference epidemiological exploration of substance and cannabinoid exposure as drivers of rising US pediatric cancer rates. BMC Cancer 2021, 21, 197–230. [Google Scholar] [CrossRef]
  6. Reece, A.S.; Hulse, G.K. Contemporary epidemiology of rising atrial septal defect trends across USA 1991-2016: A combined ecological geospatiotemporal and causal inferential study. BMC Pediatrics 2020, 20, 539–550. [Google Scholar] [CrossRef] [PubMed]
  7. Reece, A.S.; Hulse, G.K. Geotemporospatial and causal inference epidemiological analysis of US survey and overview of cannabis, cannabidiol and cannabinoid genotoxicity in relation to congenital anomalies 2001–2015. BMC Pediatrics 2022, 22, 47–124. [Google Scholar] [CrossRef] [PubMed]
  8. Reece, A.S.; Hulse, G.K. Broad Spectrum epidemiological contribution of cannabis and other substances to the teratological profile of northern New South Wales: Geospatial and causal inference analysis. BMC Pharmacol. Toxicol. 2020, 21, 75–103. [Google Scholar] [CrossRef] [PubMed]
  9. Reece, A.S.; Hulse, G.K. Causal inference multiple imputation investigation of the impact of cannabinoids and other substances on ethnic differentials in US testicular cancer incidence. BMC Pharmacol. Toxicol. 2021, 22, 40–71. [Google Scholar] [CrossRef] [PubMed]
  10. Reece, A.S.; Hulse, G.K. Co-occurrence across time and space of drug- and cannabinoid- exposure and adverse mental health outcomes in the National Survey of Drug Use and Health: Combined geotemporospatial and causal inference analysis. BMC Public Health 2020, 20, 1655–1669. [Google Scholar] [CrossRef]
  11. Reece, A.S.; Hulse, G.K. Cannabis Genotoxicity and Cancer Incidence: A Highly Concordant Synthesis of European and USA Datasets. In Cannabis, Cannabinoids and Endocannabinoids. Volume 1; Preedy, V., Patel, V., Eds.; Elsevier: London, UK, 2022; in press. [Google Scholar]
  12. Reece, A.S.; Hulse, G.K. Cannabinoid Genotoxicity and Congenital Anomalies: A Convergent Synthesis of European and USA Datasets. In Cannabis, Cannabinoids and Endocannabinoids. Volume 1; Preedy, V., Patel, V., Eds.; Elsevier: London, UK, 2022; in press. [Google Scholar]
  13. Reece, A.S.; Hulse, G.K. Cannabis Teratology Explains Current Patterns of Coloradan Congenital Defects: The Contribution of Increased Cannabinoid Exposure to Rising Teratological Trends. Clin. Pediatrics 2019, 58, 1085–1123. [Google Scholar] [CrossRef] [PubMed]
  14. Reece, A.S.; Hulse, G.K. Epidemiological Associations of Various Substances and Multiple Cannabinoids with Autism in USA. Clin. Pediatrics Open Access 2019, 4, 1–20. [Google Scholar] [CrossRef] [Green Version]
  15. Reece, A.S.; Hulse, G.K. Cannabinoid- and Substance- Relationships of European Congenital Anomaly Patterns: A Space-Time Panel Regression and Causal Inferential Study. Environ. Epigenetics 2022, 8, 1–40. [Google Scholar] [CrossRef] [PubMed]
  16. Reece, A.S.; Hulse, G.K. Geospatiotemporal and Causal Inference Study of Cannabis and Other Drugs as Risk Factors for Female Breast Cancer USA 2003-2017. Environ. Epigenetics 2022, 2022, 1–22. [Google Scholar] [CrossRef]
  17. Reece, A.S.; Hulse, G.K. Cannabis Consumption Patterns Explain the East-West Gradient in Canadian Neural Tube Defect Incidence: An Ecological Study. Glob. Pediatrics Health 2019, 6, 1–12. [Google Scholar] [CrossRef] [Green Version]
  18. Reece, A.S.; Hulse, G.K. Canadian Cannabis Consumption and Patterns of Congenital Anomalies: An Ecological Geospatial Analysis. J. Addict. Med. 2020, 14, e195–e210. [Google Scholar] [CrossRef]
  19. Forrester, M.B.; Merz, R.D. Risk of selected birth defects with prenatal illicit drug use, Hawaii, 1986–2002. J. Toxicol. Environ. Health 2007, 70, 7–18. [Google Scholar] [CrossRef] [PubMed]
  20. Reece, A.S.; Hulse, G.K. Quadruple convergence—Rising cannabis prevalence, intensity, concentration and use disorder treatment. Lancet Reg. Health Eur. 2021, 10, 100245–100246. [Google Scholar] [CrossRef]
  21. Reece, A.S.; Hulse, G.K. Epidemiological Overview of Cannabis- and Substance- Carcinogenesis in Europe: A Lagged Causal Inferential Panel Regression Modelling and Marginal Effects Study. 2022; manuscript submitted. [Google Scholar]
  22. Reece, A.S.; Hulse, G.K. Cannabis in Pregnancy—Rejoinder, Exposition and Cautionary Tales. Psychiatr. Times 2020, 37. Available online: https://www.psychiatrictimes.com/view/cannabis-pregnancy-rejoinder-exposition-cautionary-tales (accessed on 18 September 2022).
  23. Reece, A.S.; Hulse, G.K. Epidemiological Overview of Multidimensional Chromosomal and Genome Toxicity of Cannabis Exposure in Congenital Anomalies and Cancer Development. Sci. Rep. 2021, 11, 13892–13912. [Google Scholar]
  24. Reece, A.S. Rapid Response: Cannabinoid Genotoxic Trifecta—Cancerogenesis, Clinical Teratogenesis and Cellular Ageing. Br. Med. J. 2022, 376, n3114. Available online: https://www.bmj.com/content/376/bmj.n3114/rr-1 (accessed on 18 September 2022).
  25. Reece, A.S. Limblessness: Cannabinoids Inhibit Key Embryonic Morphogens both Directly and Epigenomically. Br. Med. J. 2022, 376, n3114. [Google Scholar]
  26. Reece, A.S.; Hulse, G.K. Geospatiotemporal and Causal Inferential Epidemiological Survey and Exploration of Cannabinoid- and Substance- Related Carcinogenesis in USA 2003–2017. In Epidemiology of Cannabis: Genotoxicity and Neurotoxicity, Epigenomics and Aging; Elsevier: New York, NY, USA; Volume 1, in press.
  27. Reece, A.S.; Hulse, G.K. European Epidemiological Patterns of Cannabis- and Substance- Related Congenital Body Wall Anomalies: Geospatiotemporal and Causal Inferential Study. Intern. J. Environ. Res. Public Health 2022, 19, 9027. [Google Scholar] [CrossRef] [PubMed]
  28. Reece, A.S.; Hulse, G.K. Cannabis- and Substance- Related Epidemiological Patterns of Chromosomal Congenital Anomalies in Europe: Geospatiotemporal and Causal Inferential Study. Int. J. Environ. Res. Public Health 2022, 19, 11208. [Google Scholar] [CrossRef]
  29. Reece, A.S.; Hulse, G.K. State Trends of Cannabis Liberalization as a Causal Driver of Increasing Testicular Cancer Rates across the USA. Int. J. Environ. Res. Public Health 2022, 19, 12759. [Google Scholar] [CrossRef] [PubMed]
  30. Reece, A.S.; Hulse, G.K. Epidemiology of Δ8THC-Related Carcinogenesis in USA: A Panel Regression and Causal Inferential Study. Int. J. Environ. Res. Public Health 2022, 19, 7726. [Google Scholar] [CrossRef]
  31. Reece, A.S.; Hulse, G.K. Epidemiological association of cannabinoid- and drug- exposures and sociodemographic factors with limb reduction defects across USA 1989–2016: A geotemporospatial study. Spat. Spatio-Temporal Epidemiol. 2022, 41, 100480–100490. [Google Scholar] [CrossRef]
  32. Manthey, J.; Freeman, T.P.; Kilian, C.; Lopez-Pelayo, H.; Rehm, J. Public health monitoring of cannabis use in Europe: Prevalence of use, cannabis potency, and treatment rates. Lancet Reg. Health Eur. 2021, 10, 100227–200237. [Google Scholar] [CrossRef]
  33. Reece, A.S.; Hulse, G.K. Epigenomic and Other Evidence for Cannabis-Induced Aging Contextualized in a Synthetic Epidemiologic Overview of Cannabinoid-Related Teratogenesis and Cannabinoid-Related Carcinogenesis. Mendeley Data, 2022; manuscript submitted. [Google Scholar]
  34. Reece, A.S.; Norman, A.; Hulse, G.K. Cannabis exposure as an interactive cardiovascular risk factor and accelerant of organismal ageing: A longitudinal study. BMJ Open 2016, 6, e011891–e011901. [Google Scholar] [CrossRef] [Green Version]
  35. Reece, A.S.; Hulse, G.K. Extending the “Paracentral Dogma” of biology with the metabolome: Implications for understanding genomic-glycomic-metabolic-epigenomic synchronization. Engineering 2022, in press. [CrossRef]
  36. Reece, A.S.; Hulse, G.K. Cannabis, Cannabidiol, Cannabinoids and Multigenerational Policy. Engineering 2022, in press. [CrossRef]
  37. Huang, H.F.S.; Nahas, G.G.; Hembree, W.C. Effects of Marijuana Inhalation on Spermatogenesis of the Rat. In Marijuana in Medicine; Nahas, G.G., Sutin, K.M., Harvey, D.J., Agurell, S., Eds.; Human Press: Totowa, NJ, USA; New York, NY, USA, 1999; Volume 1, pp. 359–366. [Google Scholar]
  38. Zimmerman, A.M.; Zimmerman, S.; Raj, A.Y. Effects of Cannabinoids on Spermatogensis in Mice. In Marijuana and Medicine; Nahas, G.G., Sutin, K.M., Harvey, D.J., Agurell, S., Eds.; Human Press: Totowa, NJ, USA; New York, NY, USA, 1999; Volume 1, pp. 347–358. [Google Scholar]
  39. Morishima, A. Effects of cannabis and natural cannabinoids on chromosomes and ova. NIDA Res. Monogr. 1984, 44, 25–45. [Google Scholar] [PubMed]
  40. Rossato, M.; Ion Popa, F.; Ferigo, M.; Clari, G.; Foresta, C. Human sperm express cannabinoid receptor Cb1, the activation of which inhibits motility, acrosome reaction, and mitochondrial function. J. Clin. Endocrinol. Metab. 2005, 90, 984–991. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  41. Rossato, M.; Pagano, C.; Vettor, R. The cannabinoid system and male reproductive functions. J. Neuroendocrinol. 2008, 20 (Suppl. 1), 90–93. [Google Scholar] [CrossRef] [PubMed]
  42. Chioccarelli, T.; Cacciola, G.; Altucci, L.; Lewis, S.E.; Simon, L.; Ricci, G.; Ledent, C.; Meccariello, R.; Fasano, S.; Pierantoni, R.; et al. Cannabinoid receptor 1 influences chromatin remodeling in mouse spermatids by affecting content of transition protein 2 mRNA and histone displacement. Endocrinology 2010, 151, 5017–5029. [Google Scholar] [CrossRef]
  43. Russo, C.; Ferk, F.; Mišík, M.; Ropek, N.; Nersesyan, A.; Mejri, D.; Holzmann, K.; Lavorgna, M.; Isidori, M.; Knasmüller, S. Low doses of widely consumed cannabinoids (cannabidiol and cannabidivarin) cause DNA damage and chromosomal aberrations in human-derived cells. Arch. Toxicol. 2019, 93, 179–188. [Google Scholar] [CrossRef] [Green Version]
  44. Stenchever, M.A.; Kunysz, T.J.; Allen, M.A. Chromosome breakage in users of marihuana. Am. J. Obstet. Gynecol. 1974, 118, 106–113. [Google Scholar] [CrossRef]
  45. Leuchtenberger, C.; Leuchtenberger, R. Morphological and cytochemical effects of marijuana cigarette smoke on epithelioid cells of lung explants from mice. Nature 1971, 234, 227–229. [Google Scholar] [CrossRef]
  46. McClintock, B. The Production of Homozygous Deficient Tissues with Mutant Characteristics by Means of the Aberrant Mitotic Behavior of Ring-Shaped Chromosomes. Genetics 1938, 23, 315–376. [Google Scholar] [CrossRef]
  47. Shen, H.; Shih, J.; Hollern, D.P.; Wang, L.; Bowlby, R.; Tickoo, S.K.; Thorsson, V.; Mungall, A.J.; Newton, Y.; Hegde, A.M.; et al. Integrated Molecular Characterization of Testicular Germ Cell Tumors. Cell Rep. 2018, 23, 3392–3406. [Google Scholar] [CrossRef]
  48. DiNieri, J.A.; Wang, X.; Szutorisz, H.; Spano, S.M.; Kaur, J.; Casaccia, P.; Dow-Edwards, D.; Hurd, Y.L. Maternal cannabis use alters ventral striatal dopamine D2 gene regulation in the offspring. Biol. Psychiatry 2011, 70, 763–769. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  49. Szutorisz, H.; DiNieri, J.A.; Sweet, E.; Egervari, G.; Michaelides, M.; Carter, J.M.; Ren, Y.; Miller, M.L.; Blitzer, R.D.; Hurd, Y.L. Parental THC exposure leads to compulsive heroin-seeking and altered striatal synaptic plasticity in the subsequent generation. Neuropsychopharmacology 2014, 39, 1315–1323. [Google Scholar] [CrossRef] [Green Version]
  50. Watson, C.T.; Szutorisz, H.; Garg, P.; Martin, Q.; Landry, J.A.; Sharp, A.J.; Hurd, Y.L. Genome-Wide DNA Methylation Profiling Reveals Epigenetic Changes in the Rat Nucleus Accumbens Associated with Cross-Generational Effects of Adolescent THC Exposure. Neuropsychopharmacology 2015, 40, 2993–3005. [Google Scholar] [CrossRef] [Green Version]
  51. Szutorisz, H.; Hurd, Y.L. Epigenetic Effects of Cannabis Exposure. Biol. Psychiatry 2016, 79, 586–594. [Google Scholar] [CrossRef] [Green Version]
  52. Szutorisz, H.; Hurd, Y.L. High times for cannabis: Epigenetic imprint and its legacy on brain and behavior. Neurosci. Biobehav. Rev. 2018, 85, 93–101. [Google Scholar] [CrossRef]
  53. Ellis, R.J.; Bara, A.; Vargas, C.A.; Frick, A.L.; Loh, E.; Landry, J.; Uzamere, T.O.; Callens, J.E.; Martin, Q.; Rajarajan, P.; et al. Prenatal Δ(9)-Tetrahydrocannabinol Exposure in Males Leads to Motivational Disturbances Related to Striatal Epigenetic Dysregulation. Biol. Psychiatry 2021, 92, 127–138. [Google Scholar] [CrossRef]
  54. Murphy, S.K.; Itchon-Ramos, N.; Visco, Z.; Huang, Z.; Grenier, C.; Schrott, R.; Acharya, K.; Boudreau, M.H.; Price, T.M.; Raburn, D.J.; et al. Cannabinoid exposure and altered DNA methylation in rat and human sperm. Epigenetics 2018, 13, 1208–1221. [Google Scholar] [CrossRef] [Green Version]
  55. Schrott, R.; Murphy, S.K.; Modliszewski, J.L.; King, D.E.; Hill, B.; Itchon-Ramos, N.; Raburn, D.; Price, T.; Levin, E.D.; Vandrey, R.; et al. Refraining from use diminishes cannabis-associated epigenetic changes in human sperm. Environ. Epigenetics 2021, 7, 1–10. [Google Scholar] [CrossRef]
  56. Blevins, R.D.; Regan, J.D. delta-9-Tetrahydrocannabinol: Effect on macromolecular synthesis in human and other mammalian cells. Arch. Toxicol. 1976, 35, 127–135. [Google Scholar] [CrossRef] [PubMed]
  57. McClean, D.K.; Zimmerman, A.M. Action of delta 9-tetrahydrocannabinol on cell division and macromolecular synthesis in division-synchronized protozoa. Pharmacology 1976, 14, 307–321. [Google Scholar] [CrossRef] [PubMed]
  58. Nahas, G.G.; Morishima, A.; Desoize, B. Effects of cannabinoids on macromolecular synthesis and replication of cultured lymphocytes. Fed. Proc. 1977, 36, 1748–1752. [Google Scholar] [PubMed]
  59. Mon, M.J.; Jansing, R.L.; Doggett, S.; Stein, J.L.; Stein, G.S. Influence of delta9-tetrahydrocannabinol on cell proliferation and macromolecular biosynthesis in human cells. Biochem. Pharmacol. 1978, 27, 1759–1765. [Google Scholar] [CrossRef]
  60. Mon, M.J.; Haas, A.E.; Stein, J.L.; Stein, G.S. Influence of psychoactive and nonpsychoactive cannabinoids on cell proliferation and macromolecular biosynthesis in human cells. Biochem. Pharmacol. 1981, 30, 31–43. [Google Scholar] [CrossRef]
  61. Mon, M.J.; Haas, A.E.; Stein, J.L.; Stein, G.S. Influence of psychoactive and nonpsychoactive cannabinoids on chromatin structure and function in human cells. Biochem. Pharmacol. 1981, 30, 45–58. [Google Scholar] [CrossRef]
  62. Yang, X.; Hegde, V.L.; Rao, R.; Zhang, J.; Nagarkatti, P.S.; Nagarkatti, M. Histone modifications are associated with Delta9-tetrahydrocannabinol-mediated alterations in antigen-specific T cell responses. J. Biol. Chem. 2014, 289, 18707–18718. [Google Scholar] [CrossRef] [PubMed]
  63. Mehrnoush, V.; De Lima, S.G.; Kotb, A.; Hyndman, M.E. The association of bladder cancer and Cannabis: A systematic review. Arch. Ital. Urol. Androl. 2022, 94, 248–251. [Google Scholar] [CrossRef]
  64. Payne, K.S.; Mazur, D.J.; Hotaling, J.M.; Pastuszak, A.W. Cannabis and Male Fertility: A Systematic Review. J. Urol. 2019, 202, 674–681. [Google Scholar] [CrossRef] [Green Version]
  65. Busch, F.W.; Seid, D.A.; Wei, E.T. Mutagenic activity of marihuana smoke condensates. Cancer Lett. 1979, 6, 319–324. [Google Scholar] [CrossRef]
  66. Zimmerman, A.M.; Raj, A.Y. Influence of cannabinoids on somatic cells in vivo. Pharmacology 1980, 21, 277–287. [Google Scholar] [CrossRef]
  67. Tahir, S.K.; Zimmerman, A.M. Influence of marihuana on cellular structures and biochemical activities. Pharmacol. Biochem. Behav. 1991, 40, 617–623. [Google Scholar] [CrossRef]
  68. Vela, G.; Martín, S.; García-Gil, L.; Crespo, J.A.; Ruiz-Gayo, M.; Fernández-Ruiz, J.J.; Garcia-Lecumberri, C.; Pelaprat, D.; Fuentes, J.A.; Ramos, J.A.; et al. Maternal exposure to delta9-tetrahydrocannabinol facilitates morphine self-administration behavior and changes regional binding to central mu opioid receptors in adult offspring female rats. Brain Res. 1998, 807, 101–109. [Google Scholar] [CrossRef]
  69. Koller, V.J.; Auwarter, V.; Grummt, T.; Moosmann, B.; Misik, M.; Knasmuller, S. Investigation of the in vitro toxicological properties of the synthetic cannabimimetic drug CP-47,497-C8. Toxicol. Appl. Pharmacol. 2014, 277, 164–171. [Google Scholar] [CrossRef] [PubMed]
  70. Koller, V.J.; Ferk, F.; Al-Serori, H.; Mišík, M.; Nersesyan, A.; Auwärter, V.; Grummt, T.; Knasmuller, S. Genotoxic properties of representatives of alkylindazoles and aminoalkyl-indoles which are consumed as synthetic cannabinoids. Food Chem. Toxicol. 2015, 80, 130–136. [Google Scholar] [CrossRef] [PubMed]
  71. Price, P.J.; Suk, W.A.; Spahn, G.J.; Freeman, A.E. Transformation of Fischer rat embryo cells by the combined action of murine leukemia virus and (-)-trans- 9 -tetrahydrocannabinol. Proc. Soc. Exp. Biol. Med. 1972, 140, 454–456. [Google Scholar] [CrossRef]
  72. Hölzel, B.N.; Pfannkuche, K.; Allner, B.; Allner, H.T.; Hescheler, J.; Derichsweiler, D.; Hollert, H.; Schiwy, A.; Brendt, J.; Schaffeld, M.; et al. Following the adverse outcome pathway from micronucleus to cancer using H2B-eGFP transgenic healthy stem cells. Arch. Toxicol. 2020, 94, 3265–3280. [Google Scholar] [CrossRef] [PubMed]
  73. Tahir, S.K.; Trogadis, J.E.; Stevens, J.K.; Zimmerman, A.M. Cytoskeletal organization following cannabinoid treatment in undifferentiated and differentiated PC12 cells. Biochem. Cell Biol. 1992, 70, 1159–1173. [Google Scholar] [CrossRef]
  74. Sarafian, T.A.; Kouyoumjian, S.; Khoshaghideh, F.; Tashkin, D.P.; Roth, M.D. Delta 9-tetrahydrocannabinol disrupts mitochondrial function and cell energetics. Am. J. Physiol. 2003, 284, L298–L306. [Google Scholar]
  75. Sarafian, T.A.; Habib, N.; Oldham, M.; Seeram, N.; Lee, R.P.; Lin, L.; Tashkin, D.P.; Roth, M.D. Inhaled marijuana smoke disrupts mitochondrial energetics in pulmonary epithelial cells in vivo. Am. J. Physiol. 2006, 290, L1202–L1209. [Google Scholar] [CrossRef]
  76. Morimoto, S.; Tanaka, Y.; Sasaki, K.; Tanaka, H.; Fukamizu, T.; Shoyama, Y.; Shoyama, Y.; Taura, F. Identification and characterization of cannabinoids that induce cell death through mitochondrial permeability transition in Cannabis leaf cells. J. Biol. Chem. 2007, 282, 20739–20751. [Google Scholar] [CrossRef] [Green Version]
  77. Fisar, Z.; Singh, N.; Hroudova, J. Cannabinoid-induced changes in respiration of brain mitochondria. Toxicol. Lett. 2014, 231, 62–71. [Google Scholar] [CrossRef]
  78. Singh, N.; Hroudova, J.; Fisar, Z. Cannabinoid-Induced Changes in the Activity of Electron Transport Chain Complexes of Brain Mitochondria. J. Mol. Neurosci. 2015, 56, 926–931. [Google Scholar] [CrossRef] [PubMed]
  79. Gant, J. Scientists are baffled by spatter of babies born without hands or arms in France, as investigation fails to discover a cause. In Daily Mail; Daily Mail: London, UK, 2019. [Google Scholar]
  80. Agence France-Presse in Paris. France-Presse in Paris. France to investigate cause of upper limb defects in babies. In The Guardian; The Guardian: London, UK, 2018. [Google Scholar]
  81. Willsher, K. Baby arm defects prompt nationwide investigation in France. In Guardian; The Guardian: London, UK, 2018. [Google Scholar]
  82. Babies Born with Deformed Hands Spark Investigation in Germany. Available online: https://edition.cnn.com/2019/09/16/health/hand-deformities-babies-gelsenkirchen-germany-intl-scli-grm/index.html (accessed on 18 September 2022).
  83. VACTERL Association. Available online: https://www.gosh.nhs.uk/conditions-and-treatments/conditions-we-treat/vacterl-association-0/ (accessed on 1 January 2022).
  84. Reece, A.S.; Hulse, G.K. Epidemiological Patterns of Cannabis- and Substance- Related General Congenital Anomalies Across Europe 2010–2019: Space-Time and Causal Inference Study. 2022; manuscript submitted. [Google Scholar]
  85. Eurocat Data: Prevalence Charts and Tables. Available online: https://eu-rd-platform.jrc.ec.europa.eu/eurocat/eurocat-data/prevalence_en (accessed on 1 January 2022).
  86. Global Health Observatory. Available online: https://www.who.int/data/gho/data/indicators/indicator-details/GHO/total-(recorded-unrecorded)-alcohol-per-capita-(15-)-consumption (accessed on 1 October 2021).
  87. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Statistical Bulletin 2021—Prevalence of Drug Use. Available online: https://www.emcdda.europa.eu/data/stats2021/gps_en (accessed on 1 October 2021).
  88. The World Bank. Crude Data: Adjusted Net National Income per Capita (Current US$). Available online: https://data.worldbank.org/indicator/NY.ADJ.NNTY.PC.CD (accessed on 1 October 2021).
  89. R: A Language and Environment for Statistical Computing. Available online: https://cran.r-project.org/ (accessed on 1 October 2021).
  90. Wickham, H.; Averick, M.; Bryan, J.; Chang, W.; McGowan, L.D.; Francios, R.; Groelmund, G.; Hayes, A.; Henry, L.; Hester, J.; et al. Welcome to the Tidyverse. J. Open Source Softw. 2019, 4, 1686–1691. [Google Scholar] [CrossRef] [Green Version]
  91. Pebesma, E. Simple Features for R: Standardized Support for Spatial Vector Data. R J. 2018, 10, 439–446. [Google Scholar] [CrossRef] [Green Version]
  92. Viridis: Default Color Maps from ‘matplotlib’. Available online: https://CRAN.R-project.org/package=viridis (accessed on 1 October 2021).
  93. Colorplaner: Ggplot2 Extension to Visualize Two Variables Per Color Aesthetic Through Colorspace Projection. Available online: https://github.com/wmurphyrd/colorplaner (accessed on 1 October 2021).
  94. Pinheiro, J.; Bates, D.; DebRoy, S.; Sarkar, D.; Team, R.C. Linear and Nonlinear Mixed Effects Models. R Package Version 2020, 3, 1–89. [Google Scholar]
  95. Broom.Mixed: Tidying Methods for Mixed Models. Available online: http://github.com/bbolker/broom.mixed (accessed on 1 October 2021).
  96. Broom: Convert Statistical Objects into Tidy Tibbles. Available online: https://CRAN.R-project.org/package=broom (accessed on 1 October 2021).
  97. Leeper, T.J. Margins: Marginal Effects for Model Objects; Leeper, T.J., Ed.; R package version 0.3.26; Central R Archive Network: Houston, TX, USA, 2021; Volume 1, pp. 1–36. [Google Scholar]
  98. Wright, M.N.; Ziegler, A. ranger: A Fast Implementation of Random Forests for High Dimensional Data in C++ and R. J. Stat. Softw. 2017, 77, 1–17. [Google Scholar] [CrossRef] [Green Version]
  99. Greenwell, B.M.; Boehmke, B.C. Variable Importance Plots—An Introduction to the vip Package. R J. 2021, 12, 343–366. [Google Scholar] [CrossRef]
  100. Package ‘plm’. Available online: https://cran.r-project.org/web/packages/plm/plm.pdf (accessed on 1 October 2021).
  101. Bivand, R.; Anselin, L.; Berke, O.; Bernat, A.; Carvalho, M.; Chun, Y.; Dormann, C.; Dray, S.; Halbersma, R.; Lewis-Koh, N.; et al. The spdep Package; CRAN (Central R-Archive Network): Trieste, Italy, 2007; pp. 1–143. [Google Scholar]
  102. Millo, G.; Piras, G. splm: Spatial Panel Data Models in R. J. Stat. Softw. 2012, 47, 1–38. [Google Scholar] [CrossRef]
  103. Millo, G.; Piras, G. Package ‘splm’; CRAN (Central R-Archive Network): Trieste, Italy, 2018; pp. 1–27. Available online: https://cran.r-project.org/web/packages/splm/splm.pdf (accessed on 1 October 2021).
  104. Croissant, Y.; Millo, G. Panel Data Econometrics with R; John Wiley and Sons: Oxford, UK, 2019. [Google Scholar]
  105. Wal, W.; Geskus, R. ipw: An R Package for Inverse Probability Weighting. J. Stat. Softw. 2011, 43, 1–23. [Google Scholar] [CrossRef] [Green Version]
  106. VanderWeele, T.J.; Ding, P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann. Intern. Med. 2017, 167, 268–274. [Google Scholar] [CrossRef] [Green Version]
  107. VanderWeele, T.J.; Martin, J.N.; Mathur, M.B. E-values and incidence density sampling. Epidemiology 2020, 31, e51–e52. [Google Scholar] [CrossRef]
  108. VanderWeele, T.J.; Mathur, M.B. Commentary: Developing best-practice guidelines for the reporting of E-values. Int. J. Epidemiol. 2020, 49, 1495–1497. [Google Scholar] [CrossRef] [PubMed]
  109. VanderWeele, T.J.; Ding, P.; Mathur, M. Technical Considerations in the Use of the E-Value. J. Causal Inference 2019, 7, 1–11. [Google Scholar] [CrossRef] [Green Version]
  110. Pearl, J.; Mackaenzie, D. The Book of Why. The New Science of Cause and Effect; Basic Books: New York, NY, USA, 2019; Volume 1. [Google Scholar]
  111. Package ‘EValue’. Available online: https://cran.r-project.org/web/packages/EValue/EValue.pdf (accessed on 1 October 2021).
  112. Hill, A.B. The Environment and Disease: Association or Causation? Proc. R Soc. Med. 1965, 58, 295–300. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  113. Reece, A.S.; Hulse, G.K. Effect of Cannabis Legalization on US Autism Incidence and Medium Term Projections. Clin. Pediatrics Open Access 2019, 4, 1–17. [Google Scholar] [CrossRef] [Green Version]
  114. Reece, A.S. Rapid Response: Known Cannabis Teratogenicity Needs to be Carefully Considered. BMJ 2018, 362, k3357. [Google Scholar]
  115. Reece, A.S.; Hulse, G.K. Impacts of cannabinoid epigenetics on human development: Reflections on Murphy et al. ‘cannabinoid exposure and altered DNA methylation in rat and human sperm’ epigenetics. Epigenetics 2019, 14, 1041–1056. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  116. Fish, E.W.; Murdaugh, L.B.; Zhang, C.; Boschen, K.E.; Boa-Amponsem, O.; Mendoza-Romero, H.N.; Tarpley, M.; Chdid, L.; Mukhopadhyay, S.; Cole, G.J.; et al. Cannabinoids exacerbate alcohol teratogenesis by a CB1-hedgehog interaction. Sci. Rep. 2019, 9, 16057–16075. [Google Scholar] [CrossRef] [Green Version]
  117. Aguado, T.; Romero, E.; Monory, K.; Palazuelos, J.; Sendtner, M.; Marsicano, G.; Lutz, B.; Guzmán, M.; Galve-Roperh, I. The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis. J. Biol. Chem. 2007, 282, 23892–23898. [Google Scholar] [CrossRef]
  118. Williams, E.J.; Walsh, F.S.; Doherty, P. The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. J. Cell Biol. 2003, 160, 481–486. [Google Scholar] [CrossRef] [Green Version]
  119. Birerdinc, A.; Jarrar, M.; Stotish, T.; Randhawa, M.; Baranova, A. Manipulating molecular switches in brown adipocytes and their precursors: A therapeutic potential. Prog. Lipid Res. 2013, 52, 51–61. [Google Scholar] [CrossRef]
  120. Richard, D.; Picard, F. Brown fat biology and thermogenesis. Front. Biosci. 2011, 16, 1233–1260. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  121. Xu, T.R.; Yang, Y.; Ward, R.; Gao, L.; Liu, Y. Orexin receptors: Multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders. Cell. Signal. 2013, 25, 2413–2423. [Google Scholar] [CrossRef] [PubMed]
  122. Fraher, D.; Ellis, M.K.; Morrison, S.; McGee, S.L.; Ward, A.C.; Walder, K.; Gibert, Y. Lipid Abundance in Zebrafish Embryos Is Regulated by Complementary Actions of the Endocannabinoid System and Retinoic Acid Pathway. Endocrinology 2015, 156, 3596–3609. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  123. Kučukalić, S.; Ferić Bojić, E.; Babić, R.; Avdibegović, E.; Babić, D.; Agani, F.; Jakovljević, M.; Kučukalić, A.; Bravo Mehmedbašić, A.; Šabić Džananović, E.; et al. Genetic susceptibility to posttraumatic stress disorder: Analyses of the oxytocin receptor, retinoic acid receptor-related orphan receptor A and cannabinoid receptor 1 genes. Psychiatr. Danub. 2019, 31, 219–226. [Google Scholar] [CrossRef] [PubMed]
  124. Lee, Y.S.; Jeong, W.I. Retinoic acids and hepatic stellate cells in liver disease. J. Gastroenterol. Hepatol. 2012, 27 (Suppl. 2), 75–79. [Google Scholar] [CrossRef]
  125. Ungricht, R.; Guibbal, L.; Lasbennes, M.C.; Orsini, V.; Beibel, M.; Waldt, A.; Cuttat, R.; Carbone, W.; Basler, A.; Roma, G.; et al. Genome-wide screening in human kidney organoids identifies developmental and disease-related aspects of nephrogenesis. Cell Stem Cell 2022, 29, 160–175.e167. [Google Scholar] [CrossRef]
  126. Carlson, B.M. Human Embryology and Developmental Biology; Elsevier: Philadelphia, PA, USA, 2019. [Google Scholar]
Figure 1. Bivariate plots of selected uronephrological congenital anomalies against various substances.
Figure 1. Bivariate plots of selected uronephrological congenital anomalies against various substances.
Ijerph 19 13769 g001
Table 10. E-Value List.
Table 10. E-Value List.
No.E-Value EstimateLower Bound E-Value
13.41 × 101223.30 × 1081
21.18 × 101031.36 × 1031
31.45 × 10911.08 × 1030
45.23 × 10721.67 × 1026
56.01 × 10674.98 × 1023
66.23 × 10631.24 × 1017
73.34 × 10471.14 × 1010
85.81 × 10281.39 × 109
94.09 × 10181.95 × 108
105.96 × 10172.01 × 106
111.21 × 10171.22 × 105
122.18 × 10131.15 × 105
133.51 × 1093.52 × 104
146.69 × 1082.03 × 104
154.51 × 1081.46 × 103
162.33 × 1071258.11
176.89 × 106303.56
182.74 × 105285.07
191.61 × 105119.49
201.23 × 10583.68
218.150 × 10483.66
226.62 × 10456.63
232.73 × 10443.52
246.62 × 10343.51
253540.0022.36
26955.3217.85
27954.9513.74
28606.0113.62
29365.389.43
30273.009.28
31252.919.09
32162.578.35
33161.317.02
3482.565.47
3567.005.45
3659.955.18
3743.564.73
3842.813.75
3921.283.38
4015.853.23
4111.73.13
4210.523.06
439.682.51
449.682.38
459.032.10
468.582.02
477.242.02
486.581.89
495.011.62
502.861.60
512.651.60
Table 16. EWAS Hits from Schrott Dataset for Significantly Differentially Methylated Regions for.Uronephrological Congenital Anomalies.
Table 16. EWAS Hits from Schrott Dataset for Significantly Differentially Methylated Regions for.Uronephrological Congenital Anomalies.
Functional AnnotationStatusPageNumber Genes Identifiedp-Value
Congenital Anomalies
Congenital anomalies of kidney and urinary tractWithdrawal35190.003850
Familial congenital anomalies of kidney and urinary tractWithdrawal35280.004400
Urological diseasesWithdrawal35710.007010
Renal agenesisWithdrawal31150.000429
Renal tubular morphologyWithdrawal31380.000606
Renal morphology & developmentWithdrawal322160.002160
Morphology Urinary systemWithdrawal322170.002200
Renal lesionsWithdrawal322480.002200
Renal tubular abnormalityWithdrawal32370.002550
Urinary tract cancerWithdrawal320840.001890
Male Cancers
Male genital neoplasmWithdrawal341600.000675
Male genital neoplasmDependence2791531.14 × 10−8
Malignant male genital neoplasmDependence2791511.60 × 10−8
Prostate cancerDependence2791482.88 × 10−8
Prostate cancerWithdrawal340595.33 × 10−4
Prostate cancer cell adhesionWithdrawal35710.007010
Female Cancers
Female genital neoplasmWithdrawal349780.003030
Female genital neoplasmWithdrawal350790.003460
Female genital adenocarcinomaDependence2721971.84 × 10−11
Female genital carcinomaDependence2732152.05 × 10−11
Female genital carcinomaDependence2762768.95 × 10−11
Table 20. EWAS Hits from Schrott Dataset for Significantly Differentially Methylated Regions for. Major Genes of Nephrogenesis II—Wnt’s.
Table 20. EWAS Hits from Schrott Dataset for Significantly Differentially Methylated Regions for. Major Genes of Nephrogenesis II—Wnt’s.
Nearest Gene NamePageFunctional AnnotationNumber Genes Identifiedp-Value
WNT3A239Head and neck cancer3567.73 × 10−20
WNT8B239Head and neck cancer3567.73 × 10−20
WNT3A239Head and neck cancer3427.74 × 10−20
WNT8B239Head and neck cancer3427.74 × 10−20
WNT3A240Head and neck cancer3333.34 × 10−19
WNT8B240Head and neck cancer3333.34 × 10−19
WNT3A240Abdominal carcinoma3623.64 × 10−19
WNT8B240Abdominal carcinoma3623.64 × 10−19
WNT3A241Solid cancer3816.93 × 10−18
WNT8B241Solid cancer3816.93 × 10−18
WNT3A241Thyroid cancer3181.21 × 10−17
WNT8B241Thyroid cancer3181.21 × 10−17
WNT3A242Thyroid cancer3191.26 × 10−17
WNT8B242Thyroid cancer3191.26 × 10−17
WNT3A242Endocrine tumour3211.44 × 10−17
WNT8B242Endocrine tumour3211.44 × 10−17
Table 21. EWAS Hits from Schrott Dataset for Significantly Differentially Methylated Regions for. Major Genes of Nephrogenesis III—ROCK1.
Table 21. EWAS Hits from Schrott Dataset for Significantly Differentially Methylated Regions for. Major Genes of Nephrogenesis III—ROCK1.
Nearest Gene NamePageFunctional AnnotationNumber Genes Identifiedp-ValueBonferroni Adjusted p-Value
ROCK1236Focal Adhesion390.0009340.226633
ROCK1236Vascular Smooth Muscle250.0018620.400987
ROCK1236cGMP-PKG signalling300.0038950.658065
ROCK1237Actin Cytoskeleton370.0045870.717564
ROCK1237Sphingolipid signalling240.0055960.786305
ROCK1237Axon guidance240.0111780.954555
ROCK1237Oxytocin signalling250.0390311.000000
ROCK1237TGFβ signalling160.0402471.000000
ROCK1237cAMP signalling310.0441171.000000
ROCK1237Leukocyte transendothelial migration200.0467341.000000
ROCK1238Cancer pathways540.0677701.000000
ROCK1238Platelet activation210.0778661.000000
Table 22. EWAS Hits from Schrott Dataset for Significantly Differentially Methylated Regions. For TGFβ—Signalling.
Table 22. EWAS Hits from Schrott Dataset for Significantly Differentially Methylated Regions. For TGFβ—Signalling.
Nearest Gene NamePageStatusFunctional AnnotationNumber Genes Identifiedp-ValueBonferroni Adjusted p-Value
TGFβ
TGFB150DependenceFibrosis 2.53 × 10−60.011012
TGFB1237 Chronic myeloid leukaemia167.73 × 10−200.095040
TGFB1237 Colorectal cancer140.0046260.988843
TGFB1237 Hippo signalling260.0040470.998936
TGFB1237 MAPK pathway390.0075161.000000
TGFB1237 TGFβ signalling160.0402461.000000
TGFB1238 Cancer pathways540.0677701.000000
TGFB1238 Amoebiasis180.0725791.000000
Nearest Gene NamePageStatusGene NumberChromosome Numberp-ValueBonferroni Adjusted p-Value
SMADs
SMAD26DependenceENSG00000175387189.32 × 10−90.000632
SMAD726DependenceENSG00000101665186.18 × 10−70.005518
SMAD253DependenceENSG00000175387182.90 × 10−60.011688
SMAD985DependenceENSG00000120693137.47 × 10−60.018446
SMAD6125WithdrawalENSG00000137834152.26 × 10−80.001125
SMAD3166WithdrawalENSG00000166949152.96 × 10−60.012904
SMAD7169WithdrawalENSG00000101665183.40 × 10−60.013798
SMAD2184WithdrawalENSG00000175387185.65 × 10−60.017449
SMAD3209WithdrawalENSG00000166949151.07 × 10−50.023594
SMAD2236 ENSG00000175387180.003911
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Reece, A.S.; Hulse, G.K. Epidemiological Patterns of Cannabis- and Substance- Related Congenital Uronephrological Anomalies in Europe: Geospatiotemporal and Causal Inferential Study. Int. J. Environ. Res. Public Health 2022, 19, 13769. https://doi.org/10.3390/ijerph192113769

AMA Style

Reece AS, Hulse GK. Epidemiological Patterns of Cannabis- and Substance- Related Congenital Uronephrological Anomalies in Europe: Geospatiotemporal and Causal Inferential Study. International Journal of Environmental Research and Public Health. 2022; 19(21):13769. https://doi.org/10.3390/ijerph192113769

Chicago/Turabian Style

Reece, Albert Stuart, and Gary Kenneth Hulse. 2022. "Epidemiological Patterns of Cannabis- and Substance- Related Congenital Uronephrological Anomalies in Europe: Geospatiotemporal and Causal Inferential Study" International Journal of Environmental Research and Public Health 19, no. 21: 13769. https://doi.org/10.3390/ijerph192113769

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop